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INTRODUCTION 
 
What is expected from an experimental thesis it is a series of data justifying an idea, 
supporting a theory, leaving results that say: we think to do this, we perform several 
experiments and finally we have one or more solid answers. I do not have more answers than 
the first day of my PhD. I have more questions. So I can‟t say I am at the end of a journey, nor 
I believe to have better answer. I only hope to have better questions and in the future I wish to 
have the right ones… 
Laboratory practice is quite simple. It needs care and some experience but everyone with a bit 
of intelligence and practical ability can perform good experiments. 
When we make a reaction, we feel able to generate something new or to control physical and 
chemical phenomena… and it is simply astonishing! Let‟s think to crystallization, kinetic 
control of reactions, column chromatography and so on! 
Although the enormous number of sometime incontrollable variables operating in our 
reactions, practical and theoretical aspects must be complementary to guide us in predicting 
the outcome of a reaction. 
Our reality is made of atoms, electrons and their interactions. We can classify interatomic 
interactions, made of electron density, as bonded or non-bonded. We can further subdivide 
bonded interactions into ionic, metallic, covalent, coordinate covalent, and partial bonds (as at 
transition  states), and we can subdivide non-bonded interactions into charge transfer 
interactions, hydrogen bonds, dipolar interactions, dispersion (London forces or VdW 
interaction), and so forth. Mixed cases are also possible, such as polar covalent (e.g., an HF 
bond is about 50% ionic and 50% covalent) or a much more complicated range of possibilities 
for non-bonded interactions. When we put reactants together, a lots (or sometimes all) of the 
interactions listed above act at the same time and the balance of the playing forces leads 
electrons to rearrange in a preferred way that we try to foresight! Everything can guide the 
forces toward a predictable result: interaction with solvent, relative disposition of the 
reactant, number of beats between molecules, partial charges and so on. To understand how 
our reactions go, today we have in hand some good models. From an historical point of view 
our theory has been generated in the early „900 with relativity theory. In particular the work 
of Erwin Schrödinger on eigenvalue1 that contains the famous Schrödinger‟s equation able to 
describe every system from a particle to the universe in the most complete way. Such an 
equation is almost impossible to solve as is. This is simply understandable if we consider that 
for a single particle, only for position, there are 4 variables, 3 for space and 1 for time. Two 
particles lead to 8 variables and so on. Moreover in the calculation, at each time, we must 
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consider both the relative position and energy of every particle to each other, the kinetic 
energy etc. When we say “particle” we mean electron or nucleus, thus for h2 molecule, in 
vacuum, Schrödinger‟s equation must account for 4 particles and 16 variables each one 
influencing the other only for their position! It was immediately clear that approximations are 
needed. In the subsequent years the extraordinary effort of an entire generation of physics 
and mathematics leads to the first utilizable approximation that finally lead in the‟70, ‟80 and 
‟90, when computer becomes fast enough, to great results, even in perfect accordance with 
experimental data. Theory, algorithms and computers are still evolving and today we can 
perform on our pc calculation able to reproduce experimental data! 
Here are the questions: how are our theories reliable? How is our computer reliable? How are 
the approximations reliable? 
So we must be really careful when we start a computational study, we have to be confident 
about our computer, we have to choose the theory that better reproduce the data we are 
looking for and also is not too engaging in term of computational time; but the critical point is 
the approximation we make. If we want to consider all the variables involved in a reaction the 
system surely becomes too large, we can‟t consider even a “molecule” of our system comprising 
all reactants, molecules of solvent, external energy, reaction intermediates without utilizing 
some further approximation (for example the solvent is normally approximated by a model). 
Today the only way to overcome this problem is still the experience of the chemist and his 
careful evaluation may lead to right approximation obviously within the human error. 
In spite of all this variables in this work we reach some good results, so we finally can 
conclude that our theory and our practice, although not perfect, are good enough to be an 
invaluable instrument. 
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GENERAL PART 
 
Our research is always oriented to synthesis and functionalization of different types of 
heterocycles with biological interest. In particular we focus our attention on N-containing 
heterocycles because they are the more represented in natural products and drugs. Synthesis 
and functionalization of this structure is nowadays an established reality with several 
limitations such as construction of high complexity policycles, green procedure, extend scope 
and reduce limitation of already known reactions.   
Our research has been focused on various aspects of heterocycles synthesis and reactivity. For 
this purpose we usually use transition metals catalysis, among which Pd has a central role. In 
fact this catalytic method allows synthesis otherwise impossible. It is not a case that 2010 
chemistry Nobel Prize winners are professors who work on palladium catalysis.  In our 
experience, and always taking theory with us, Pd catalyst is a great force in our hand to guide 
reactions where we would like! 
Palladium catalysis has achieved the status of an indispensable tool for the current organic 
synthesis and a wealth of reviews and books on organopalladium chemistry has been 
published.2 
Palladium is a member of the Nickel triad in the Periodic Table. Palladium complexes exist in 
three oxidation states: Pd(0), Pd(II) and Pd(IV). The facile interconversion between these 
oxidation states is responsible for the broad utility of palladium in organic chemistry, since 
each oxidation state exhibits different chemistry. 
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Pd(0)-catalyzed reactions 
 
1. Heck type arylations on azines and diazines 
Among basic types of palladium-catalyzed transformations, the Heck reaction and related 
chemistry occupies a special place. During the last thirty-five years this reaction has emerged 
as highly efficient and well documented mild procedure for carbon-carbon bonds formation.3  
The success of the Heck reaction is subject to the identification of the class of Heck reaction in 
terms of both the type of alkene (whether electron rich or poor) and the electrophile (whether a 
halide or a trifluoromethanesulfonate is the leaving group). In order to maximize the 
conversion is then essential to select the appropriate conditions. The reaction consists on the 
coupling of an aryl or vinyl halide with an olefin, according to scheme 1. 
 
Scheme 1 
H
Pd(0)
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The readily available starting materials make this strategy useful for construction and 
functionalization of carbocyclic and heterocyclic systems.4  
The mechanism proposes that the active catalytic unit is the coordinately unsaturated 14 
electron species PdL2. This would seem reasonable since PdL2 is electron rich and nucleophilic 
in character and has vacant sites so that the organic electrophile RX can undergo oxidative 
addition to give the known RPdX intermediate in which the R group (aryl or vinyl) is σ-bonded 
to the Pd(II). A vacant site must now be created to receives and activate the alkene, so that a 
neutral RPdX(CH2=CHR) species is formed. The coordinated alkene then undergoes syn 
addition to form an unstable σ-bonded complex, which will rotate around the carbon-carbon 
bond so that the palladium and β-hydrogen are syn coplanar, and β-hydride elimination takes 
place to generate the observed trans substituted alkene and the catalytically inactive HPdX as 
outlined in Figure 2. The base which must be present to enact a successful catalytic cycle, 
eliminates HX to regenerate Pd(0) and the whole cycle repeats. 
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A more detailed scheme of the whole catalytic cycle of Heck-type reaction can be obtained 
merging some recent excellent works on the subject5 with the established knowledge superbly 
reported in Neghishi‟s book.3b  
We can see in scheme 3 that PdL2 is not the only species able to undergo oxidative addition 
but also mono-ligated Pd species was experimentally observed and may be responsible for the 
first step. It is also important to note that only soluble Pd cluster can lead to active palladium, 
so concentration plays a central role. Various molecules, for example the solvent, and ions may 
act as ligands for Pd and sometimes this kind of coordination makes reaction possible thanks 
to their electronic effects.  
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Scheme 3 
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The general procedure involves up to 1 mol% of catalyst, 2 equiv of triarylphosphine 
(stabilizing the arylpalladated intermediates and catalytic Pd in solution). The rate-limiting 
step is the oxidative addition of ArX that depends on the nature of X (ArI > ArOTf > ArBr >> 
ArCl). The temperature range is 70-120 °C and the most common medium for the reaction is 
one of the aprotic polar solvents, such as DMF, DMA, DMSO and CH3CN. The Heck reaction 
is also reported to be highly regioselective as shown in Scheme 1. Depending on which ligand 
is used, α-regioisomers or β-regioisomers may be selectively formed. 
For intramolecular Heck cyclization the reaction conditions appear to vary depending on 
whether a tertiary or quaternary centre is being formed, on the ring size and the 
stereochemistry of the alkene. Depending upon the geometry (enforced by the substrate 
structure), the alkene can approach the palladium-carbon σ-bond by two limiting orientations, 
the eclipsed orientation and the twisted orientation (scheme 4). Either insertion orientation 
can access to the cyclization product but eclipsed orientation is preferred: in this case the 
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palladium-carbon σ-bond approaches the alkene in the plane of the alkene σ-bond en route to 
the insertion product. 
 
Scheme 4 
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Arenes also participate in the intramolecular Heck reaction. Mechanistically, these reactions 
differ from alkene reactions and are thought to occur via reductive elimination of the 
intermediate A. Intermediate A could arise from an intramolecular electrophilic aromatic 
substitution or a Pd(IV) intermediate (scheme 5). The literature reports experimental supports 
for either reaction pathway. Afterwards we will discuss our hypothesis on this matter on the 
base of the results obtained. 
 
Scheme 5 
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For the construction of aryl-aryl bonds the above mentioned Heck-type arylations are of 
particular interest.6  Respect to the cross-coupling reactions, the advantages of these reactions 
consist in the opportunity to start from very simple and readily available reactants, through 
the substitution of one of the functionalized arenes, normally the organometallic coupling 
partner, with arenes, obtaining an economical and practical advantage.  Besides this 
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methodology was pointed out as environmental benign strategy owed to low waste production 
and improvement in term of atom economy. 
Moreover bi(hetero)aryl structural motif  is a predominant feature in many pharmaceutically 
relevant and biologically active compounds7 as shown in fig. 1 where we report for a single 
JMC issue the pages were we found these structures. 
 
Figure 1 
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Our previous contribution in this area concerned the intramolecular direct arylations of 
electron-rich heterocycles bearing both electron-withdrawing and electron-donor substituents 
in the presence of Pd(0)-catalyst, under different conditions (ligand or ligand-free conditions).8  
This process allowed us a straighforward method to generate aza-substituted ring fused to 
(hetero)arenes. 
In contrast to the numbers of papers reporting the utilization of electron-rich heterocycles in 
the direct arylation process9 both as intra- and intermolecular reactions, the direct arylation of 
simple aromatic rings remains a significant challenge10 and even more the use of electron-poor 
heterocycles, such as azines and diazines is rare. In these cases the few reported results gave 
five or six  member rings formation, in very low yields and following harsh reaction 
conditions.11 Recently Fagnou reported the intermolecular arylations of azines and diazines 
exploiting the trasformation of these substrates on the more electron-rich  azine- and diazine 
N-oxides.12 We report here our results on direct arylation on electron-poor arenes; the 
described results are much more noteworthy due to the literature data on the poor reactivity 
of these substrates.13  
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Starting from nicotinic acids 1a,b and 3-quinolinecarboxylic acid 1c, the reaction with the 2-
iodoaniline 2 followed by methylation on the amides 3a-c, gave the corresponding tertiary 
amides 4a-c suitable substrates for the direct arylation reaction (Scheme 1). The 
intramolecular process, obtained using Pd(OAc)2 as catalyst, AcOK as base, TBAC as additive 
and DMA as solvent, afforded two regioisomers 5a-c and 6a-c arising from the cyclization on 
position 2 or 4 of the pyridyl ring, in 3:1 ratio in favour of the para position.  Similarly the 
reaction of the isonicotinic acid 7 with 2-iodoaniline 2 or 2-bromo-3-aminopyridine 8 and 
subsequent methylation of 9a,b afforded the amide 10a,b, the cyclization of which gave the 
trycyclic systems 11a,b. Although usually direct arylation for rings of low reactivity 
necessitated the use of electron-rich and sterically-hindered trialkylphosphines.14  
Compared to the procedure used previously, it should be noted that ligand-free conditions 
(Jeffery‟s conditions) have been successfully used. On the contrary, optimizing the reaction 
conditions, we discovered that the presence of the base and polar solvent are required to 
obtain the products. In fact the absence of AcOK or solvent different than DMA or DMF, 
resulted in unreacted substrate. The addition of TBAC improves the yields. If temperatures 
higher than 100 °C are used for similar reactions and in most cases heating for several hours 
to days is necessary, the reaction time (45 min) was considerably reduced when the use of 
microwaves was tested. 
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To probe the feasibility of the arylation reactions on electron-poor heterocycles, we considered 
other substrates as the amides arising from the 1,2-, 1,3- and 1,4-diazines carboxylic acids 12-
14. In these cases, the amides 16-18 were obtained by reaction with 2-iodo-N-methylaniline 15 
on the unisolated acyl chloride. In fact the methylation step carried out on the secondary 
amide must be avoided giving methylation also on the heterocyclic nitrogen atom. The cyclized 
products 19-21 were formed in one step from the corresponding amides. In the case of amide 
16, the cyclization reaction gave two regioisomers 19a,b in 1:1 ratio, corresponding to the 
cyclization product respectively on position 3 and 5 of the piridazyl ring, showing any 
selectivity in coupling reaction. (scheme 7). 
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To consider the possible influence of the ring size on the cyclization process and with the aim 
to obtain more challenging seven-membered rings, we focused our attention on the 
homologous of pyridine carboxylic acid, the pyridin-2-yl acetic acid 22 from which the 
corresponding amide was prepared via unisolable acyl chloride in the presence of 
triethylamine. The methylation step necessary to avoid the nitrogen coordination to 
palladium, gave in this case double methylation, involving benzylic carbon. The obtained 
tertiary amide 24 was then treated following the reported conditions, to give in very good yield 
the cyclized product 25 as shown in Scheme 8. 
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Scheme 8 
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Several pathways have been proposed for the palladium-catalyzed arylation of aromatic 
compounds, the process depending on the (hetero) aromatic substrate, base, ligand and solvent 
used. The involvement of an electrophilic aromatic substitution (SEAr) was commonly accepted 
for π-electron-rich substrates,15 while other mechanisms such as Heck-type process,16 or 
proton-abstraction could be envisaged for different substrates.  
In all the proposed mechanisms, the first step generally occurs via oxidative addition of the 
aryl halide to the transition metal to give the intermediate A, followed by different possible 
carbon-carbon bond formation paths (scheme 9). The electrophilic aromatic substitution (SEAr) 
suggested for electron-rich heterocyclic substrates, through the intermediate B gave the 
palladacycle structure D, which in turn gets the cyclized product via reductive elimination of 
Pd(0) with the contemporary catalyst regeneration. This hypothesis is not applicable in the 
case of electron-deficient heterocyclic nucleus.  
Recent work indicated the Heck-type process rather unlikely,17 and the literature data showed 
as a more probable mechanism the concerted proton abstraction path (by the halogen anion or 
by an external base) operating via a four-membered transition state as showed for the 
intermediate C.18  
The truthfulness of the latter mechanism was proven through the comparison of two different 
arenes and the observation that the more electron-deficient one reacted preferentially.19  
 This outcome was inconsistent with a SEAr mechanism. 
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2. Functionalization of indolines through Pd(0)-catalyzed 
amination reactions 
 
The amination reaction is nowadays one of the most powerful tools to obtain C-N bond 
formation.20  
Palladium competes strongly with non-precious metals like copper, nickel, and, more recently, 
iron to this aim. Even though nickel, copper, and iron, are truly more cost-effective, palladium-
catalyzed bond formation presents some advantages: 
1. Palladium catalysts often possess a higher activity than their metal alternatives 
enabling the conversion of less reactive substrates 
2.  Pd works at relatively low temperatures  
3. Pd posses higher catalyst turnover numbers (TONs) up to 106.  
Considering this reaction typology, the use of weak base has been demonstrated very 
important to leave intact other functional groups. Moreover the use of different ligands and 
their optimization lead to the improvement of yields and applicability. Our work tried to 
further enlarge the scope and to use environmental friendly procedures and to develop 
economic and scalable synthesis to shift the use of this reaction from research to industry 
 
 A typical example of amination reaction between an aryl halides and an amine is reported 
below (scheme 10).21 
 
Scheme 10 
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The spectrum of suitable amine is very large, in fact using right condition almost everyone can 
react; the only limitation is the presence of other reacting functional groups. 
 As aromatic partner iodides and bromides are the most suitable, but also chlorides and 
triflates may be successfully used. Pd catalyst employed are in general Pd2(dba)3 or Pd(OAc)2. 
10 to 10-6 % 
Different phosphine and carbene ligands may be used selected on the basis of their steric and 
electronic properties. On the basis of the choice reaction may be successful or not; they play a 
central role in the oxidative addition (the rate limiting step), in Pd solubilization (preventing 
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precipitation as inactive palladium black) and in making Pd coordination site available for 
catalysis; some example are reported below in fig. 2: 
 
Figure 2 
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The concentration of phosphine ligand is very important because in some cases an excess may 
results in a “phosphine poisoning” of the catalytic palladium. 
 For what concern bases, organic or inorganic bases can be used. Weak bases as K2CO3 or 
Cs2CO3 need larger excess than the standard 1.4/1 used for t-BuOK. Recent studies show that 
working in a large excess of K2CO3 up to 5/1 may give better results. 
The role of the solvent is not  well known; in general the better ones are toluene or THF but 
many other have been tested giving good results; sometimes ter-Butanol or water are used . 
Rare cases of solvent free are reported, for example alumina supported reaction.22 
The mechanism of this reaction was deeply investigated by Buchwald and Hartwig.23  
The accepted catalytic cycle, when bidentate phosphine are used is reported in scheme 11. At 
first, a Pd(0) complex is formed from Pd(0) precatalyst or after reduction of Pd(OAc)2 and 
phosphine ligand. This step play a central role because it is possible the formation of an 
inactive tetracoordinate Pd (0) lying out of the catalytic cycle(phosphine poisoning). The di-
coordinate Pd(0) complex undergoes oxidative addition of aryl halide and the resulting 
arylpalladium halide is converted to an arylpalladium amide in the presence amine and base. 
The arylpalladium amide can then undergo reductive elimination to form the desired 
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arylamine product and regenerate double coordinated Pd(0). This reaction results zero-order 
in amine, first-order in arylhalide, and inverse first-order in added ligand.  
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Regarding the synthesis of heterocyclic systems, Pd-catalyzed reactions have been 
extensively applied.2h  
The amination reaction is a substantial part of our research and we apply this reaction 
expecially to indoles.24 Nowadays indole chemistry is broadly known and studied, so we like to 
focus on a little different heterocycle: indoline. 
In spite of indoline chemistry is very interesting, it‟s not so explored. The indoline skeleton is 
an ubiquitous scaffold found in a range of biologically active alkaloids and pharmaceutically 
active compounds25 as shown in fig. 3. 
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Figure 3 
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Indolines have also been successfully employed as chiral auxiliaries in asymmetric synthesis.26 
and references cited therein. On the other hand indolines are also useful for various 
applications ranging from dyes, dye sensitized solar cell, to fuel cell (H2 storage).27   
The initial efforts to search for the best catalytic conditions were made on indoline and the 
good partner heteroarylhalide 2-bromopyridine (scheme 12 and table 1). 
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Scheme 12 
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Table 1. 
Entry Catalysta Ligandb Base T °C/h Yield (%) 
1 2% A 2%  BINAP 5  Cs2CO3 120°C 24 10 
2 2% A 
2% 1,1′-
Bis(diphenylphosphino)ferrocene 
1,4 t-BuOK 120°C 24h 5 
3 2% A 
4% 2-Dicyclohexylphosphino-2′-
(N,N-  dimethylamino)biphenyl 
1,4 t-BuOK 140°C 10 min 5 
4 2% A 4% IAPU 5  Cs2CO3 120°C 24h 25 
5 5% B 10% BINAP 1,4 t-BuOK 120°C  24h 60 
6 1% B 2% BINAP 1,4 t-BuOK 120°C 24h 40 
7 5% B 10% BINAP 2 Cs2CO3 100°C 24h 70 
8 1% B 4% IAPU 1,4 t-BuOK 100°C 24h 80 
9 1% B 4% IAPU 1,5 Cs2CO3 100°C 24h 55 
10 1% B 4% IAPU 5 K2CO3 100°C 24h 75 
11 0,5% B 2% IAPU 5 K2CO3 100°C 24h 75 
[a] A=Pd(OAc)2   B=Pd2(dba)3 [b] IAPU= (2,8,9-triisobutyl-2,5,8,9-tetraaza-1-phospha-bicyclo[3.3.3]undecane  
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The two better conditions found (entries 7 and 8) are:  
a) Pd2(dba)3, IAPU,28 t-BuOK, toluene 
b)  Pd2(dba)3, BINAP, Cs2CO3, toluene 
The first one gives better yield, the second uses a weaker basis. The use of a large excess of 
K2CO3 as in the entries 10 and 11 allow the use of IAPU even without strong bases and give us 
the impulse to develop our work toward a totally new approach. 
Surprisingly a lot of these simple products have not yet been synthesized.  
Nowadays the goal of an organic chemist is not only to obtain the product but also to make 
new kind of synthesis as sustainable as possible. Green chemistry and sustainability are 
becoming more and more important in everyday organic synthesis.29 
 Within this subject, the elimination of solvents is advantageous, since supply, purification, 
and disposal of these can be omitted. The accompanying reduction of solvent waste is the 
major motivation for the development of a broad variety of solvent-free synthetic reaction 
protocols.30 
While reactions are often carried out in a solvent-free manner using classical laboratory 
equipment, the application of microwave heating represented an added value. From an 
economical point of view, according to the results reported by Gronnow et al.,31 the use of 
microwave irradiation heating process was expected to significantly reduce (up to 85-fold) the 
amount of energy required to perform the reaction (by comparison with what would be 
necessary in a thermal conventional way). In these terms, this procedure can also be 
considered as a green process. Besides a lot of solvent-free procedures are carried out utilizing 
one of the reactants as solvent, substantially limiting the scope.  
What is the meaning of sustainability? Two points are the key to apply it: 
1. Use of reagents with the lowest environmental impact (that is: greener solvents or no 
solvents at all, no hazardous elements or a very low concentration of it, no waste 
products or few waste and above all the waste must be rather safe). 
2. Lowering of operators, energy and reagents costs. 
To develop a sustainable method we apply the aforesaid criteria: no solvent, no waste, lowest 
Pd load, use of microwaves to reduce time and energy consumption. 
Starting from the observation that C-N bond formation is improved by excess base we test the 
reaction with the reacting mixture (indoline, bromopyridine, Pd2(dba)3, IAPU) and  K2CO3  as 
“solvent”. Because this “solvent” is not a liquid, we have first of all dissolved the mixture in 
DCM to obtain an homogeneous distribution of reactants, then we add a very large excess of 
K2CO3 and then we remove the DCM in vacuum to recover it for the next reaction. In this way 
(SOLVENT “QUASI” FREE reaction) the only solvent used is reusable many times! 
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Moreover microwave irradiation is an advantageous method to furnish energy to the mixture 
reagents; thermal heating do not allow reaction. 
With a great pleasure we found that the above-mentioned conditions work well! 
The use of K2CO3 deserves some comments, in particular three conditions to be satisfied: 
1. It must be finely powdered; this is due to the total exposed area which grows a lot 
reducing particle size. When we try to do this reaction on granular K2CO3 the reaction 
yield drop dramatically to one third. 
2. It must be adequately hydrated. If K2CO3 is absolutely dry reaction does not take place. 
But if K2CO3 is too hydrated reaction yield drop to one half.  
3. It is necessary to well pack the powder after its introduction in the reactor.  
The traditional and SOLVENT “QUASI” FREE reactions are comparable in term of yields (78 
vs 75%) but SOLVENT “QUASI” FREE shows no presence of by-product (as oxidation product 
indole, dehalogenated aryl halide, Ullman type biaryl product) and also when the yields are 
scarce we recover only unreacted substrates. Table 2 shows the comparison yields between the 
traditional thermal heating and the microwaves irradiation SOLVENT “QUASI” FREE. 
Considering the synthetic importance of chiral indolines, in particular as building blocks for 
drugs and as chiral auxiliaries in asymmetric synthesis, enantiopure 2-substituted indolines 
are obtained when the reaction is performed on chiral substrates (Table 2, entry 11). In fact 
despite the presence of a base the (S)-indoline-2-carboxylic acid give (S)-1-(4-nitrophenyl) 
indoline with enantiomeric purity better than 99.5% as confirmed by chiral HPLC analysis 
with an AD chiral column and in comparison with a sample of the corresponding racemic 
mixture synthesized starting from (±)-indoline-2-carboxylic acid. This result also represents a 
rare example in which a base-sensitive substrate has been employed for palladium-catalyzed 
amination reaction.32   
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TABLE 2. N-ARYLATION OF INDOLINES WITH ARYL BROMIDES 
ENTRY[a] REACTION PRODUCT  YIELD Δ 
 YIELD MW 
1 
N
NN
H
N
Br
+
 
26 78 76 
2 
N
NN
H
N
Br
+
 
27 0 24 
3 NH
+ N
Br
COOCH3
COOCH3 
28 30 62 
4 NH
+ N
Br
NO2
NO2 
29 5 75 
5 NH
+ N
Br
CN
CN 
30 57 71 
6 
Br
+
N
OCH3
OCH3
N
H
 
31 68 77 
7 
N
H
+
N
Br
 
32 52 59 
8 N
H
+
N
Br
F
O
O
O
O
F  
33 70 45 
9 N
H
+
N
Br
 
34 68 68 
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10 NH
+ N
Br
NO2
NO2  
35 5 65 
11 
N
H
+
N
Br
NO2
NO2
COOH
COOH
 
 
36 0 53 
12 NH
+
N
Br
NO2
NO2
COOMe
COOMe
+
 
37 51 54 
 
 
TABLE 3. N-ARYLATION OF INDOLINES WITH ARYL CHLORIDES AND 
IODIDES 
ENTRY[a] REACTION PRODUCT YIELD Δ 
YIELD MW 
1 
N
NN
H
N
Cl
+
 
26 46 66 
2 
N
NN
H
N
Cl
+
 
27 70 80 
3 NH
+ N
Cl
COOCH3
COOCH3 
28 37 50 
4 NH
+ N
Cl
NO2
NO2 
29 59 67 
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5 NH
+ N
Cl
CN
CN  
30 40 60 
6 
Cl
+
N
OCH3
OCH3
N
H
 
31 72 66 
7 
I
+
N
OCH3
OCH3
N
H
 
31 88 84 
8 
N
H
+
N
I
 
32 68 71 
9 N
H
+
N
Cl
NO2
O
O
O
O
NO2  
38 75 48 
10 N
H
+
NN
Cl
N
O
O
O
O
 
39 73 50 
 
 
The alternative catalytic system to obtain C-N bond formation in the presence of base 
sensitive groups and especially carboxylic acid is Cu(II) in polar solvent. We test this condition 
to synthesize N-substituted indoline-2-carboxylic acid and found a substantial inferior yield 
(30%).  
Reasoning about the Pd-catalyzed C-N bond formation, we wonder how much phosphines 
should be important once Pd is fixed on carbonate. The use of ligands in Pd-catalyzed 
amination reactions is something established; their use enable synthesis otherwise hard or 
impossible to achieve. The problem is that ligands are sometimes more expensive than 
precious metals and are not so safe as waste. We decide to try ligandless conditions.  In the 
initial solubilisation step the role of phosphine may be crucial avoiding Pd black aggregation 
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and consequent catalyst inactivation. What we must avoid, in the absence of phosphines is Pd 
aggregation.  
In order to avoid Pd particles aggregates as Pd black, removal of the solvent is the critical 
step.  
The reaction we choose as model is between indoline and 4-bromonitrobenzene (scheme 14) 
because it gives good yield in SOLVENT “QUASI” FREE protocol and is prone to all parasite 
reactions.  
 
Scheme 14 
N
H
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First of all we try a low catalyst yield and condition similar to SOLVENT-“QUASI” FREE with 
2 minutes of beats for compression. The aspect of the powder in the MW reactor after heating 
show a red coloration (our product is orange-red) near temperature probe where powder is 
more compressed, so we think that the low yield may be due to an insufficient compression. 
Following this idea we push powder with 4 minutes of beats and try to elevate the reaction 
temperature. Yield results tripled. To improve our results we double the Pd load. Yield results 
increased up to 34%. The subsequent trials lead us to optimize Pd loading to 1% leaving other 
parameters unchanged.  In table 4 we report all the experiment we perform.   
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TABLE 4. N-ARYLATION OF INDOLINES SOLVENT&LIGAND FREE 
Entry Reaction Product Yield 
1 NH
+ N
Cl
NO2
NO2  
29 0% 
2 N
H
+ N
Br
NO2
NO2  
29 
60% 
 
3 N
H
+ N
Br
NO2
NO2  
35 48% 
4 N
H
+
N
Br
NO2
NO2
COOH
COOH
 
36 
 
40% 
 
5 
N
NN
H
N
Cl
+
 
26 0% 
6 
N
NN
H
N
Br
+
 
26 60% 
7 
N
NN
H
N
Br
+
 
27 35% 
25 
 
8 
 
N
N
H
Br
+
 
32 
 
40% 
9 
 
N
N
H
I
+
 
33 
 
25% 
10 
 
N
N
H
Br
+
 
34 
 
35% 
11 
N
N
H
Br
+
OMe
OMe 
31 
 
50% 
12 
N
N
H
I
+
OMe
OMe 
31 
 
38% 
13 N
H
+
N
NO2
Br
NO2  
40 
 
50% 
14 NH2
+
NH
NO2
Br
NO2 
41 
 
25% 
15 N
H
+
N
NO2
Br
NO2
COOMe
COOMe
 
37 
 
35% 
26 
 
16 
Br
NO2
+
N
H
O
N
O
NO2 
42 0% 
17 
Br
NO2
+
NH2
H
N
NO2 
43 0% 
18 N
H
+ N
Br
NO2
NO2
O
O
 
44 0% 
19 N
H
+
N
Br
NO2
NO2
O
O
 
45 traces 
20 NH
+ N
Br
NO2
NO2  
46 15% 
 
As we can note in table 4, some common feature are evident: 
1. Aryl bromides and iodides react, chlorides are unsuitable for this method. 
2. Aryl bromides are more efficient than iodides (maybe for Iodide poisoning of Pd) 
3. Yields are moderate but we do not recover by-product, after reaction only product and 
reactant are recovered. 
4. Solvent and ligand FREE condition work on aromatic amines, secondary one are 
preferred. Amides seem to be nonreactive.  
This new procedure is the first example of solvent and ligand-free palladium-catalyzed 
amination reaction. Although not exceptional yield and limited scope reduce its applicability 
maybe this is a good starting point for future development. Conditions seems to be very mild 
for reactants, in fact reagents do not undergoes other parasite reactions, a typical problem of 
Buchwald-Hartwig reaction when condition are not optimized to obtain yields over 90%. When 
we try to prolong reaction time we can‟t observe any improvement and in some cases few by-
products appears. The use of higher temperature is a suitable way to improve yield, but 
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heating at 160°C is sometimes difficult due to the absence of solvent and the advantage is not 
so great, not above 10% yield increase. 
There are some parameters to be careful about: procedure must be followed rigorously, 
different degree of particle size of K2CO3 influence a lot the outcome and the time spent in 
mortar and pestle use is critical; different Pd2dba3 may influence yield up to react or not; the 
initial microwave oven power must be very high to overcome the inertial barrier of the solid 
reacting mixture.  
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3. Benzodiazepines synthesis through -allyl Pd-complex 
1,4-Benzodiazepines play an important role in medicinal chemistry due to a wide range of 
pharmaceutical applications.33 
1,4-Benzodiazepin-5-ones, one of the most significant classes of these molecules, are 
recognized as being endowed with anxiolytic, anticonvulsant, antiepileptic, muscle relaxant, 
antidepressant, sedative, and hypnotic activities related to the treatment of CNS disorders.34  
Moreover, this range of therapeutic activities has been significantly enhanced by annulation of 
the benzodiazepine skeleton to another carbo- or heterocyclic ring. Tricyclic 1,4-benzodiazepin-
5-one systems, beyond solving benzodiazepine overdose problems, as in the case of flumazenil 
(fig. 4, compound A),35 are also antihistaminic compounds,like tarpane (fig. 4, compound B),36 
antibiotics, like the pyrrolo-fused abbeymicin (fig. 4, compound C)37 and antitumor agents, 
such as structures D (Fig. 4).38  More recently, inspired by the attention given to bretazenil 
(fig. 4, compound E) due to its potential application in neurodegenerative diseases,39 some 
tetracyclic 1,4-benzodiazepinones have appeared in the literature. These structures have the 
benzodiazepine nucleus fused to different hetero- and carbocycles such as pyrimidines, 
imidazoles, 1,2,4-triazoles, pyrazoles, benzopyrans, or naphthalenes.40 
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Among the several procedures reported in articles and patents to synthesize 1,4-
benzodiazepin-5-ones, approaches involving the formation of the 1–2 nitrogen–carbon bond as 
the final step are commonly used. Intramolecular cyclization of amines with carbonyls41 or 
acetals/thioacetals,42 reductive cyclization of nitro derivatives with carbonyls,43 intramolecular 
1,3-dipolar cycloadditions of azides44 and nitrilimines45 to alkenes and/or alkynes, aza-Wittig 
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ringclosure of iminophosphoranyls with carbonyls,46 intramolecular Michael addition of 
amines to enones,47 intramolecular nucleophilic substitutions by aniline derivatives,48  ring-
opening reactions of amines on furan moieties,49  intramolecular Pd-catalyzed cyclizations,50 
and the cyclization of amines with nitriles51 on differently substituted benzamides have 
proven to be fruitful methodologies for promoting the formation of the nitrogen–carbon bond, 
eventually with the simultaneous construction of a new ring.  
We have developed our synthesis of a new class of tetracyclic 1,4-benzodiazepin-5-ones  
through our recent interest in allenylamide heterocyclization52 and long-time experience of 
1,3-dipolar cycloaddition reactions.53 
The starting point for planning the new synthetic strategy arose from the recent synthesis of 
the enantiopure 2-vinylimidazolidinones 48, obtained by heteroannulation of the amino-
allenylamides 47 (Scheme 15). The imidazolidinones 48 are ideal starting point for a final step 
involving a 1,3-dipolar cycloaddition bearing a double bond as dipolarophile. 
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Our approach required the synthesis of 2-aminobenzamides 52 as suitable compounds for 
accessing the azide and nitrilimine 1,3-dipoles due to the presence of the aniline moiety. With 
this aim, the Boc-protecting group was removed by treatment with TFA to give 
imidazolidinones 49 (Scheme 16). These latter compounds were functionalized by reaction 
with 2-nitrobenzoyl chloride (50) to give the 2-nitrobenzamides 51, which in turn were reduced 
to the 2- aminobenzamides 52.  
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The diazotization of the aniline moiety permitted access to the corresponding azido 
compounds, but their intramolecular 1,3-dipolar cycloaddition furnished unstable 4,5-dihydro-
1,2,3-triazole products, which decomposed into complex mixtures with no synthetic interest. 
Such a failure prompted us to turn our attention to the nitrilimine 1,3-dipole, a well-
established functional group in the synthesis of variously substituted azoles.54  
 To this end, compounds 52 were submitted to diazotization and subsequent Japp–
Klingemann reaction55 that is, coupling with ethyl 2-chloroacetoacetate, furnished the 
hydrazonyl chlorides 53, precursors of the transient nitrilimine species 54. In fact treatment 
of 53 with triethylamine in boiling toluene gave directly the tetracyclic imidazo[2,1-
c]pyrazolo[1,5-a][1,4]-benzodiazepine-5,8-dione systems 55 (scheme 17). 
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We next examined the reactions of imidazolidinones 48 and 5-chloro- and 5-fluoro-2-
nitrobenzoyl chlorides (50a and 50b, respectively) to broaden the scope of the reaction and for 
the interest of the products from a biological point of view, having a halo-substituted 1,4-
benzodiazepine nucleus. The halide-containing products, 2-nitrobenzamides 51, 2-
aminobenzamides 52, hydrazonyl chlorides 53, and tetracyclic products 55, are presented in 
Table 1. The preparation of hydrazonyl chlorides as well as the nitrilimine cycloaddition 
reactions occurred analogously to those described for the unsubstituted 2-nitrobenzoyl 
chloride. All compounds synthesized are reported in table 5. 
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Table 5 
Imidazolidin 
ones 2-Nitrobenzamides 2-Aminobenzamides Hydrazonyl chlorides Benzodiazepinones 
HN
N
O
Ph
N
N
O
PhO
NO2
Cl
N
N
O
PhO
NH2
Cl
N
N
O
PhO
NH
Cl
N
Cl
COOEt
N
N
N
N
Cl
COOEt
O
O
Ph
H
HN
N
O
i-Pr
Ph
N
N
O
i-Pr
PhO
NO2
Cl
N
N
O
i-Pr
PhO
NH2
Cl
N
N
O
i-Pr
PhO
NH
Cl
N
Cl
COOEt
N
N
N
N
Cl
COOEt
O
i-Pr
O
Ph
H
HN
N
O
Bn
Ph
N
N
O
Bn
PhO
NO2
Cl
N
N
O
Bn
PhO
NH2
Cl
N
N
O
Bn
PhO
NH
Cl
N
Cl
COOEt
N
N
N
N
Cl
COOEt
O
Bn
O
Ph
H
49a 51aa 52aa 53aa 55aa
49b 51ba 52ba 53ba 55ba
49c 51ca 52ca 53ca 55ca
 
HN
N
O
Ph
N
N
O
PhO
NO2
F
N
N
O
PhO
NH2
F
N
N
O
PhO
NH
F
N
Cl
COOEt
N
N
N
N
F
COOEt
O
O
Ph
H
HN
N
O
i-Pr
Ph
N
N
O
i-Pr
PhO
NO2
F
N
N
O
i-Pr
PhO
NH2
F
N
N
O
i-Pr
PhO
NH
F
N
Cl
COOEt
N
N
N
N
F
COOEt
O
i-Pr
O
Ph
H
HN
N
O
Bn
Ph
N
N
O
Bn
PhO
NO2
F
N
N
O
Bn
PhO
NH2
F
N
N
O
Bn
PhO
NH
F
N
Cl
COOEt
N
N
N
N
F
COOEt
O
Bn
O
Ph
H
49a 51ab 52ab 53ab 55ab
49b 51bb 52bb 53bb 55bb
49c 51cb 52cb 53cb 55cb
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Further to the total regiochemical outcome that was expected as a consequence of the 
propargylic nature of the 1,3-dipole, the cycloaddition reaction was totally diastereoselective 
giving rise to only one diastereoisomeric product.  
The absolute configuration of the simplest term was assigned on the basis of 1H NMR NOESY 
experiments carried out on compound 55a. As shown in Figure 2, further to obvious 
interactions between the hydrogen atoms at the 2- and 5-positions of the imidazole nucleus, 
the cross-peak between the hydrogen at the 2-position of the imidazolidinone and the ortho 
hydrogen atoms on the phenyl group resulted in the determination of the S configuration of 
the newly created stereocenter and thus the (3aS,3bR,6S) diastereoisomer. The enantiomeric 
purity was proven to be better than 99.5% by HPLC analysis of compound 55a with an AD 
chiral column and in comparison with a sample of the corresponding racemic mixture 
synthesized starting from (±)-alanine. 
Figure 5 
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To deeply investigate this non-common feature we start a theoretical study. To make a more 
eclectic work we decide to compare the old wave function method HF with DFT method in 
order to see if results are in agreement and which one is the best one to solve our problem. We 
have also take a look on computational calculation cost in order to give a better overall 
evaluation.  
Further to broadly used DFT and WFT theory, today we have a new theory which could be 
seen as a complement to the classical quantum chemical tool and is able to interpreter the 
results obtained by wave function resolution in a very  familiar way for a laboratory organic 
chemist. This theory is called AIM, acronym of Atoms In Molecules (also known as QTAIM 
where QT means Quantum Theory), and was developed between ‟70 and ‟80 by R. W. F. 
BADER. He summarized his findings in a book edited in 199056 where there is explained how 
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this theory is rigorously derived only by wave function applying mathematical and physical 
theorems without arbitrary assumptions.  
AIM theory focus on interpretation of wave function results in terms of electron density. 
Applying the mathematical principles of topology it explain how we can assign to each atom in 
a molecule a defined region of space, not only in terms of electron density ρ, but also as its 
second derivative 2ρ, otherwise known as Laplacian, or even the kinetic energy density, the 
virial of the forces etc. 
The strength of AIM theory is the ability to describe bond, not only covalent bond, but also the 
ones described (erroneously) as “interaction” or particular kind of bond like H-bonds, π-π 
bonds, ionic bonds, metallic bonds, coordination bonds, VdW bonds etc.   
Such a powerful tool could lead us to interesting conclusions. When we observe how a reactant 
becomes a product, both weak and transient bond and interaction may play a very central role 
carrying to a specific kind of product (instead of the other). 
Unfortunately at the date of writing there are only few articles in which AIM theory is used to 
analyze reaction pathways;57 in particular it‟s still not clear the fundamental role played by  
AIM theory in this area. Consequently this is our purpose and we like to explore this field. 
We refer to the two possible products as reported below in fig. 6. 
Simple calculation of the two product energies don‟t give results in agreement with 
experiment: HF/631Gd  or HF/6311+Gdp provide Zero Point corrected Energy of  about 1 
Kcal/mole favorable to TRANS. B3LYP/631Gd and B3LYP/6311+Gdp give the same result 
with energy differences of about 2  Kcal/mole. Since the solvent used is always toluene, that 
doesn‟t influence a lot the outcome, as we expected, calculations with salvation model, give 
almost identical results. 
To justify our results we decide to locate the two possible TS in order to trace the reaction 
energy profile. In our hypothesis the reaction energy profile must support experimental data 
giving rise to a typical graph like the one reported below (graph 1). 
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Graph 1 
 
 
As showed we expect that while “similar-trans” starting products and TS, are more stable 
than the corresponding cis, the energy difference between trans and cis products, as we have 
already calculated, is only 1 or 2 Kcal/mol. But we also think to find an overall energetic gap 
very large in favor of cis. 
This gap is the sum of the differences between starting substrates to TS and TS to products. 
The first difference must be low to make easier for the molecule reaching its TS. This profile is 
improved when TS and reactant are similar as implied in Hammond‟s postulate. The latter 
difference must be higher because a big energy jump can be the leading force for the formation 
of one product instead of the other.  
The first step is an optimization, HF and DFT, of the four molecules involved in the reaction 
and reported in fig. 6. Products were already optimized in the early stage of our research as 
reported above. 
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The optimization of reactants is not so simple. For nitrilimine moiety, in term of geometry, we 
start from the good data find by Ponti et al.58 But we have also to face with another important 
feature: the relative position of the nitrilimine moiety to the styrene-like one. To be sure 
avoiding errors we perform a potential energy surface scan. We place H and phenyl in 
“similar-cis” and “similar-trans” position and scan the rotation of the nitrilimine moiety 
around the amidic C-N bond indicated. 
We found in fact an interesting feature: the two reactants assume a very different spatial 
disposition and “cis” reactant is less stable but with nitrilimine and double bond closer. See 
fig. 7 e fig. 8 to better understand. 
 
Figure 7 
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Figure 8 
 
 
Bearing in mind Hammond‟s postulate we could see that the “cis” reactant is very similar in 
spatial disposition to the TS; that‟s make simpler its evolution to TS. 
To locate the TS we use a strategy based on two different but, in the same time, synergic 
starting method:  
We start from optimized product, break the two bond formed in the reaction and, on the basis 
of literature data on 1,3-dipolar cycloaddiction,59 we assign the distances between dipole and 
dipolariphile double bond. First we optimize these molecules fixing the length of the partially 
formed bond, and then we try to locate the TS (fig. 9). 
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After calculation we find the reaction energy profile reported in the two graphs 2 and 3. 
 
Graph 2 
 
HF 631Gd 
Graph 3 
 
DFT B3LYP 631Gd
 
It‟s clear that results don‟t agree with experimental data: in fact in both cases TRANS product 
seems to be more stable and TRANS starting molecule is more stable too. However the 
energetic gap, as explained before, seems to be consistent with experimental data. 
In graphs 4 and 5 we try to emphasize the energetic differences enabling cis product to form.  
 
Graph 4 
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 Graph 5 
 
  
B3LYP 631Gd 
In the graph 4 we report the differences, in Kcal/mol, between TS and reactant (blue), product 
and TS (yellow). Two things are clear: first of all for “similar-trans” reactant is more difficult 
to reach its TS; second, the energetic gain in the formation of product is slightly favorable to 
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the cis transition from TS to product. To magnify this concept we can use a mathematical 
trick: plot in a graph the differences between the commutation energy:  
 
1) [(TS-transRectant)-(TS-cisReactant)] 
 
2 ) [(transProduct-TS  )-( cisProduct-TS)] 
 
In this way the first formula gives the differences of the differences in energy needed for 
reactants to reach TS, this energy is lower if the transition is favored. The second formula 
gives the differences in ΔE between product and the originating TS; these ΔE are negative and 
greater when transformation is favored so that the difference we use must be above 0 if 
transformation is favorable to cis product formation. 
 
Graph 6 
 
  HF 631Gd 
Graph 7 
 
  B3LYP 631Gd 
 
At this medium-low level of BS we already see that the energetic gap lead to CIS product, HF 
and DFT are in agreement. To convince ourselves of the truthfulness of our results we perform 
a systematic enlargement of BS up to 6-311G++2d3p and then we also make an extrapolation 
at infinite BS. In graphs 8 and 9 and in graphs 10 and 11 below we can see results at the 
higher BS used.  
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Graph 8 
 
HF 6311++G2d3p 
Graph 9 
 
B3LYP 6311++G2d3p 
 
 
Graph 10 
 
HF 6311++G2d3p 
Graph 11 
 
B3LYP 6311++G2d3p 
 
Utilizing triple split, enlarging the use of diffuse function and additional function on H and C 
gives good results for DFT and HF too, with computational time lower for DFT calculations.  
After all these calculations we can justify our experimental results considering that the overall 
gain in energy seems to push the reaction toward the CIS product. The difference between the 
two products is little, near or below the error, but decrease as basis set increase. Besides this 
fact  at the higher basis set used, in the case of HF calculation we obtain a difference of  about 
8 Kcal/mole in favor of CIS product, and almost no differences (below 0,4 Kcal/mole) for DFT. 
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We must also note that the higher basis set used places more function on hydrogen (3p) than 
on heavy atom (2d). This not well balanced basis set, also thanks to heavy use of diffuse 
functions, seems to reach better results. This fact could be due to a fortuitous case or to the 
strong influence that VdW and dispersive interaction play in our specific case. 
The question now is: how we can trust these theoretical results? If we don‟t really have in 
hand experimental results and we want to make previsions, do we foresee the right results? 
From an organic chemist point of view, the study of a reaction based on energy and ΔG, ΔH, 
ΔS is not immediately clear; sometimes we find numbers hard to interpret, other time, with 
the current instruments and approximations, we can‟t find an unambiguous answer. 
In our case it is possible that improving DFT functional, since B3LYP is somewhat dated, may 
lead to better results. On the other hand the use of a post-HF WFT method like MP2 could be 
better, but for a system of 53 atoms it becomes quite prohibitive in terms of computational 
cost.  
As reported after we have a further instrument: AIM. 
To apply AIM theory to our problem we try to investigate various aspects and features of 
electron density and his derived and subtended properties. 
First of all we try to understand if there is a correlation between several properties at the 
bond critical point (BCP) and the overall reaction result. To account for the evolution from 
reactants to products we consider the three new critical points (CP) formed at the level of TS: 
the two BCP, C-C and C-N, and the RCP (Ring Critical Point) deriving from cycloaddiction. 
We analyze the electron density, the laplacian of electron density, the kinetic energy density 
and the virial of the forces exerted at the critical points by the electron density. 
Utilizing wave function deriving from HF calculation we state some common feature. In 
particular the laplacian of ρ is always negative and superior in the trans TS.  
The electron density at the same CP for the two TS is higher for CIS both at the C-N and ring 
critical point, while it is lower for C-C BCP; we observe the same behavior for kinetic energy 
density and virial of the forces. We don‟t exactly know the real meaning of this; we can only 
formulate an interpretation: the first bond formed in cycloaddiction is the C-N bond which 
guides the generation of the RCP, and then C-C bond is formed.   
This interpretation lack of the data deriving from -2ρ that is always favorable to TRANS 
even if with little value. 
On the other hand DFT data are different because they show a laplacian favorable to CIS 
product, with electron density and virial almost equal for C-N and RCP, whilst ρ and virial of 
BCP C-C favorable to TRANS. 
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It is interesting to note that the value of laplacian are similar at every level of BS used, so we 
can conclude that results do not suffer of strong base dependencies as already noted in several 
articles(ref.). 
A deep investigation of these results and the use of higher level of theory could give better 
results.  To put a critical interpretation on computational data, we try to find a simpler, more 
reliable and rapid way able to give realistic results, in accordance with experimental one. 
This goal implies a deep understanding of the mechanism and the forces involved in the 
reaction pathways. What can guide the formation of one product instead of the other is weak 
and transient interaction, forces difficult to see and account for utilizing simply outcome of 
QM calculation. AIM theory, as said after, can account for the abovementioned “interaction” 
and characterize them. 
At this point we decide to look out for differences about the weakness of bond between the two 
TS and surprisingly we can see substantial differences that strongly justify experimental data.   
CIS TS bear three weak bond involving phenyl and H that are the two groups considered for 
the cis-trans isomerism. TRANS TS shows only one weak bond. See figure NN 
This is not all. In fact the two more bonds in CIS TS lead to two additional critical points, one 
ring CP (fig. 10, yellow arrows) and above all a cage CP (fig. 10, green arrow). This feature 
strongly pushes the reaction toward CIS product because the forces involved in this 
interaction, although invisible from standard QM calculation outcome and not high enough to 
be reliably calculated, are visible with AIM analysis and in doubtful cases could lead to a good 
solution. 
It is encouraging that this weak bond are present in AIM analysis based in every calculation, 
spanning from HF to DFT and from 6-31Gd to 6-311G++2d3p. These homogeneous results 
should arise from the basis of AIM theory: once we found equilibrium geometry, the forces are 
zero and we obtain the right distribution of the electron density. Although we can‟t trust the 
value obtained at low level of theory, we can see at a glance the interaction we couldn‟t see 
otherwise. 
In our case we state the existence of weak interaction addressing the outcome of the reaction, 
we can then move in this way to address the problem, for example we can tell that large use of 
additional basis, especially on hydrogen, lead to a better result in term of energy and is not a 
casual issue. On the other hand we can try to use DFT functional which better account for 
weak interactions. In any case we observe interaction otherwise invisible only based on wave 
function. This interaction are evident thanks to the use of AIM theory which we can say in the 
future will became surely a breakthrough mean to interpret obscure data arising from wave 
function and better understand the various aspect of organic chemistry. 
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Figure 10 
 
CIS TS, white arrow indicates BCP of weak interaction, yellow arrow indicates ring CP, green 
arrow indicates cage CP generating from weak interaction ring. 
Fig ure 11
 
 
TRANS TS, white arrow indicates BCP of weak interaction, yellow arrow indicates ring 
CP. 
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Pd(II)-catalyzed reactions 
 
4. Alkenylation of isoxazol-5-ones through Pd(II)-
catalyzed C-H activation  
In the wide range of Pd-catalyzed reactions, oxidative coupling and amination reaction of 
alkenes and alkynes have been less employed despite the easy availability of the starting 
materials, compared to the halogenated substrates necessary for reactions like the Heck 
reaction and the Buchwald-Hartwig reaction. 
The oxidative coupling is a catalytic process which allows the formation of carbon-carbon 
bond. The literature data report oxidative inter- or intra-molecular coupling like arylation of 
aromatic heterocycles and alkenylation of arenes with olefins through the cleavage of sp2 C-H 
bond in the presence of palladium complexes. Most of the applications of palladium described 
in literature use a stoichiometric amount of palladium complexes. The synthetic advantage of 
this oxidative process consists on the use of catalytic amount of palladium. 
Palladium(II) salts are electrophilic species and tend to react with electron-rich substrates 
such as olefins, alkynes and arenes. The mechanism of these processes has been extensively 
studied. The typical reaction with alkenes starts with the complexation of the olefin by Pd(II) 
salt, as reported in scheme 18 on the left side. The resulting π-olefin complex A can undergo 
an intermolecular or intra-molecular nucleophilic attack, usually at the less substituted 
vinylic carbon, to give a π-alkylpalladium(II)-complex B. The final product arises normally 
from β-hydride elimination of HPdX but also different processes may be observed.  
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With aromatic substrates different mechanism has been proposed which involves the 
electrophilic substitution of an aryl hydrogen by palladium giving C and the formation of a π-
bonded aryl-Pd(II)complex D (scheme 18, on the right side). This palladate intermediate can 
give rise to homocoupling reaction or, in the presence of alkenes, vinylic substitution reaction. 
Also in this case elimination of HPdX gives the final product. 
In situ regeneration of Pd(II) from Pd(0) is the crucial step for catalytic cycle; for this purpose, 
several re-oxidation reagents have been already reported such as copper acetate, tert-butyl 
hydroperoxide, butyl perbenzoate, BQ and oxygen. 
We try to apply this kind of reaction to isoxazol-5-ones which may act as heterocycles or 
nucleophiles.  
Isoxazol-5-ones are particular heterocycles existing in three tautomeric forms. This 
characteristic is strongly influenced by solvent as we can note in the reported NMR:  in CDCl3 
we observe the presence of CH2 and CH3 as singlet as it is possible for tautomer 1 and 3, but 
we also observe the C-H of tautomer 2 which shows the splitting of CH2 signals and is about 
50% of the other tautomer (based on relative value of integrals for CH3). 
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Scheme 19 
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Figure 12 (CDCl3) 
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In acetonitrile we still observe the two tautomers and the relative ratio is the same 2/1 in 
favor of NH or OH form.  
 
Figure 13 (CD3CN) 
 
When we observe spectra acquired in protic solvent we note that only one form is present and 
C-H tautomer is unobserved.  
Figure 14  (Methanol D4) 
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On the basis of charge separated limiting Lewis structure, we can note that there are a lot of 
possible reacting sites (scheme 20). This characteristic is a double-edged blade leading to a 
great number of synthetic possibilities but a very difficult regio- and chemo-selectivity control.  
 
Scheme 20 
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The three resonance forms are reported below associated to their possible reactivity (Figure 
15): 
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Another interesting but also problematic feature is the tautomerism of the anion, solvent and 
base dependent, easily generated even with weak bases (scheme 21). 
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Scheme 21 
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Isoxazol-5-ones could act as heterocycles or nucleophile in C-H activation reactions, especially 
in the presence of a base that generates the anions. If we look at the general catalytic cycle 
reported for oxidative coupling in our case we probably have something like scheme 22. 
 
Scheme 22 
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Previous works on Pd(II) catalyzed reactions report a solvent-based regioselectivity60 (scheme 
23 and 24). We find interesting to try the feasibility of such a kind of reaction on isoxazol-5-
ones because of the possible influence of solvent and catalytic system on the outcome. In spite 
of the difficulty we wonder if it is possible the total control of regioselectivity and to lead 
reaction exactly in the desired direction playing on simple adjustable parameters. 
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Scheme 24 
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The first problem to solve is the choice of the oxidant agent. It must be outline that with 
isoxazol-5-ones benzoquinone and MnO2 gave in good yields C-C and C-N dimerization 
derivatives61 (scheme 25). 
The second problem is the formation of by-product where isoxazol-5-ones incorporate the 
oxidant as in the case of benzoquinone.  
Table 6 shows all the trials done 
 
Scheme 25 
N
O
R1
R2
O
H
Oxydant
N
O
R1
R2
O
N
O
R1
R2
O
N
O
R1
R2
O
N
O
R1 R2
O
+
COOMe
+
+
N
O
R1
R2
O
COOMe
Pd(II)
 
 
 
 
 
50 
 
TABLE 6. OXIDANTS TESTED 
OXIDANT PRODUCT 
MnO2 Dimer +product 
Cu(OAc)2 Dimer +product 
I2 Dimer 
H2O2 Dimer/Hydroxylated 
Benzoquinone Adduct with BQ 
IodoPhenyldiAcetate Dimer + product 
Oxone Dimer 
 
Surprisingly we have found the solution to our problem in the O2. In spite of its di-
radical structure, molecular oxygen is unable to dimerize isoxazol-5-ones, at least if it is 
used at 1 atm. At this point we try to obtain a certain regioselectivity playing with different 
solvents.  
Scheme 26 
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Table 7 reports our results. 
 
TABLE 7 
Isoxazol-5-one (R,R‟) Solvent 
C-product 
57 a or b 
N-product 
58 a or b 
O-product 
59 a or b 
Me-Bn 56a AcOH 2 1 0 
Me-Bn 56a AcOH /CH3CN 1/3 1 0 0 
Me-Bn 56a AcOH /Dioxane 1/3 1 4 1 
Me-Bn 56a THF/DMF 2/1 1 0 0 
Me-Ph 56b AcOH 0 1 0 
Me-Ph 56b AcOH /CH3CN 1/3 0 0 1 
Me-Ph 56b AcOH /Dioxane 1/3 1 2 1 
Me-Ph 56b THF/DMF 2/1 0 0 1 
 
 
The reported data show that it is possible to achieve solvent-based regioselectivity, even total. 
As already reported regioselectivity is also substrate-dependent: the differences in term of 
electronic environment and sterical hindrance seem to play a role in the reaction outcome.  
Unfortunately the great drawback of isoxazol-5-ones alkenylations is the low yield. We try to 
improve outcome in different way, but till now we can‟t obtain yield better than 25%. Maybe 
the bottleneck is the balance between the oxidative recycle of Pd(II) and the parasite reaction 
that oxidant do: if we improve oxidation, increasing Pd activity, we raise-up by-product, but on 
the other hand, weak oxidation is unable to efficiently recycle Pd(II).  
This problem lead us to try another catalyst, Au(III). Gold catalysis attract lots of attention 
in the past fifteen years due to its simply usage and broad scope.62 Among the Au-catalyzed 
reactions we focus on triple bond activation which could act as C-H activation and give 
hydroalchenilation as reported in the scheme 27. The product is the same of a simple Michael 
addition, the added value that gold could gives is the regioselectivity. 
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Scheme 27 
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The simplified mechanism of this reaction (scheme 28) involves an initial coordination of the 
triple bond by gold(III) that enable the triple bonded C to react as electrophile; after the 
formation of C-C bond and production of HCl, the unstable Au-complex with the intervention 
of the HCl gives the desired product and regenerates catalytically active Au(III). 
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As we have hoped, we are succeeded improving yield up to 40% and obtain a solvent-based 
dependent regioselectivity (table 8). In every case O-product is absent, while in general C 
product is the preferred one. Testing different triple bonds lead to the conclusion that an 
electron withdrawing group is necessary for this reaction. Maybe the presence of the electron 
withdrawing group improve the effect of gold(III) lowering the electron density on the 
terminal C atom. 
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TABLE 8. Product of Au-catalyzed reactions 
Isoxazol-5-one alkine Solvent 
C-product 
57 a or b 
N-product 
58 a or b 
O-product 
59 a or b 
Me-Bn 56a Ethyl propiolate AcOH 1 1 0 
Me-Bn 56a Ethyl propiolate Dioxane 2.5 1 0 
Me-Bn 56a Ethyl propiolate CH3CN 1 0 0 
Me-Bn 56a Fenilacetilene CH3CN 0 0 0 
Me-Bn 56a 2-nitro-Fenilacetilene CH3CN 1 0 0 
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CONCLUSION 
In this thesis we exploit a wide range of different synthetic strategy to obtain or functionalize 
N-containing heterocycles. Besides we also find conditions useful for a more sustainable 
chemistry. In this field the use of transition metal catalysis seems to be contradictory, but our 
effort in reducing all the other non-green aspects and the metal load is one good way toward 
this goal. We report several reactions useful for synthesis hard to perform till now. Moreover 
we demonstrate that Pd-catalyzed amination could be performed even without a ligand and we 
hope this finding will open new possibilities. Above all we always try to understand as deep as 
we can every aspects of our synthetic work. In fact thanks to our effort in understanding 
chemistry, we realize a study that justifies an uncommon reaction feature utilizing a new 
method and applying a recent and somewhat neglected theory. 
We synthesize a number of new compounds never reported before. Among these there are a lot 
of potentially active compounds or molecules with special characteristics, useful in a wide 
range of possible applications. 
Our research already gives its results, but it seems to be still plenty of possibility and always 
with immediate applicability. On the other hand the study of the mechanisms that rule the 
reactions surely lead to new interesting results.  
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EXPERIMENTAL PART 
 
Melting points have been determined on a Büchi B-540 heating apparatus and are 
uncorrected. 1H NMR and 13C NMR spectra have been obtained on a VARIAN 200. Chemical 
shifts are given in ppm downfield from SiMe4. 13C NMR spectra are 1H-decoupled and the 
determination of the multiplicities has been achieved by the APT pulse sequence. IR spectra 
have been recorded on a Jasco FT/IR 5300 spectrophotometer. 
 
CHAPTER 1 
General procedure for the synthesis of the heteroaryl amides. 3a–c, 
9a,b and 23 
A mixture of acids 1a–c, 7 or 22 (10 mmol) and SOCl2 (10 mL, 137 mmol) was stirred at 100°C 
for 2.5 h. After evaporation of the solvent, the residue was dissolved with CH2Cl2 (20 mL). A 
solution of 2 or 8 (15 mmol) and TEA (2.1 mL, 15 mmol) in CH2Cl2 (5 mL) was added dropwise 
at 0°C. After stirring for 5 h at room temperature, the solution was washed with 5% HCl (2x20 
mL) and then with 5% aqueous NaOH (2x20 mL). The organic layer was dried (Na2SO4) and 
the solvent was evaporated under reduced pressure. The residue was chromatographed on a 
silica gel column, using CH2Cl2 as eluent, to give compounds 3, 9 and 23. 
 
      N-(2-Iodophenyl)-pyridine-3-carboxamide (3a) 
White solid, mp 134–136°C; yield 67%. IR (Nujol): 3300, 1631 cm-1. 1H NMR: d 6.92 (1H, dd, 
J¼5.0, 7.5 Hz), 7.41 (1H, dd, J¼7.5, 7.8 Hz), 7.48 (1H, dd, J¼5.0, 7.5 Hz), 7.83 (1H, d, J¼7.8 
Hz), 8.27–8.30 (1H, m), 8.32 (1H, br s, exch. D2O), 8.33–8.39 (1H, m), 8.80 (1H, d, J¼5.0 Hz), 
9.22 (1H, s). 13C NMR: d 91.1 (s), 122.6 (d), 124.1 (d), 127.0 (d), 129.8 (d), 130.6 (s), 135.6 (d), 
138.1 (s), 139.3 (d), 148.5 (d), 153.2 (d), 163.8 (s). Anal. Calcd for C12H9IN2O (324.12): C, 
44.47; H, 2.80; N, 8.64. Found: C, 44.34; H, 2.79; N, 8.80.  
 
      N-(2-Iodophenyl)-6-chloro-pyridine-3-carboxamide (3b) 
White solid, mp 142–144°C; yield 88%. IR (Nujol): 3280, 1638 cm-1. 1H NMR: d 6.88–6.96 (1H, 
m), 7.38–7.46 (1H, m), 7.49 (1H, dd, J¼0.6, 8.4 Hz), 7.82 (1H, dd, J¼1.3, 8.1 Hz), 8.20 (1H, br 
s, exch. D2O), 8.22 (1H, dd, J¼2.6, 8.4 Hz), 8.34 (1H, dd, J¼1.3, 8.1 Hz), 8.98 (1H, dd, J¼0.6, 
2.6 Hz). 13C NMR: d 90.9 (s), 122.3 (d), 124.9 (d), 127.0 (d), 129.4 (s), 129.8 (d), 137.7 (s), 138.2 
(d), 139.2 (d), 148.6 (d), 155.2 (s), 162.6 (s). Anal. Calcd for C12H8ClIN2O (358,56): C, 40.20; H, 
2.25; N, 7.81. Found: C, 40.06; H, 2.36; N, 7.94. 
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      N-(2-Iodophenyl)-quinoline-3-carboxamide (3c) 
Light brown solid, mp 221–222°C dec; yield 76%. IR (Nujol): 3290, 1640 cm-1. 1H NMR: d 
6.95–7.03 (1H, m), 7.39–7.47 (1H, m), 7.82–7.90 (2H, m), 8.00–8.09 (2H, m), 8.18 (1H, d, J¼8.4 
Hz), 8.64 (1H, d, J¼8.4 Hz), 9.27–9.28 (1H, m), 9.71 (1H, br s), 10.05 (1H, s). 13C NMR: d 91.5 
(s), 123.0 (d), 127.1 (d), 127.3 (s), 127.5 (s), 128.5 (d), 128.6 (d), 129.3 (d), 129.7 (d), 132.7 (d), 
137.9 (d), 138.1 (s), 139.2 (d), 147.5 (d), 148.1 (s), 163.3 (s). Anal. Calcd for C16H11IN2O 
(374.18): C, 51.36; H, 2.96; N, 7.49. Found: C, 51.30; H, 3.10; N, 7.56 
 
      N-(2-Iodophenyl)-pyridine-4-carboxamide16 (9a) 
White solid, mp 122–124°C (lit. mp 122–123°C); yield 80%.  
 
      N-(2-Bromopyridin-3-yl)-pyridine-4-carboxamide (9b) 
White solid, mp 139–141°C; yield 57%. IR (Nujol): 3298, 1623 cm-1. 1H NMR: d 7.35 (1H, dd, 
J¼4.5, 8.1 Hz), 7.82–7.71 (2H, overlapping), 8.17 (1H, dd, J¼1.5, 4.5 Hz), 8.54 (1H, br s, exch. 
D2O), 8.81 (1H, dd, J¼1.5, 8.1 Hz), 8.80–8.94 (2H, overlapping). 13C NMR: d 121.1 (d), 124.1 
(d), 124.2 (d), 129.3 (d), 133.4 (s), 134.0 (s), 141.1 (s), 145.7 (d), 145.8 (d), 151.4 (d), 164.0 (s). 
Anal. Calcd for C11H8BrN3O (278.11): C, 47.51; H, 2.90; N, 15.11. Found: C, 47.63; H, 3.07; N, 
15.22. 
 
      N-(2-Iodophenyl)-2-pyridin-2-yl-acetamide (23) 
White solid, mp 110–112°C; yield 53%. IR (Nujol): 3258, 1632 cm-1. 1H NMR: d 3.96 (2H, s), 
6.82 (1H, dd, J¼7.5, 7.6 Hz), 7.26–7.35 (3H, m) 7.73 (1H, dd, J¼7.8, 8.2 Hz), 7.78 (1H, d, 
J¼7.8Hz), 8.24 (1H, d, J¼8.2Hz), 8.70 (1H, d, J¼4.2 Hz), 9.88 (1H, s, exch. with D2O). 13C 
NMR: d 46.4 (t), 89.7 (s), 122.7 (d), 122.8 (d), 124.5 (d), 126.2 (d), 129.3 (d), 137.9 (d), 138.4 (s), 
139.5 (d), 149.7 (d), 155.2 (s), 167.9 (s). Anal. Calcd for C13H11IN2O (338.15): C, 46.18; H, 3.28; 
N, 8.28. Found: C, 46.30; H, 3.31; N, 8.20. 
 
General procedure for the synthesis of the N-methylheteroamides 4a–c, 10a,b and 24 
To a stirred solution of 3, 9 or 23 (2 mmol) in dry THF (15 mL) cooled to 0°C, 60% NaH (0.2 g, 
5 mmol) was added under nitrogen atmosphere. The resulting mixture was allowed to warm to 
rt; then a solution of MeI (0.37 mL, 6 mmol) in dry THF (5 mL) was added dropwise. After 4 h 
the solvent was evaporated and the residue diluted with 1 M HCl (20 mL) and extracted with 
Et2O (2x20 mL). The organic layer was dried with Na2SO4 and solvent was evaporated under 
reduced pressure. The residue was chromatographed on a silica gel column, eluent 
CH2Cl2/AcOEt 3:1. 
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      N-(2-Iodophenyl)-N-methyl-pyridine-3-carboxamide (4a) 
White solid, mp 117–118°C; yield 58%. IR (Nujol): 1641 cm-1. 1H NMR: d 3.39 (3H, s), 6.92–
6.96 (1H, m), 7.05–7.36 (3H, overlapping), 7.69–7.81 (2H, overlapping), 8.39–8.56 (2H, 
overlapping). 13C NMR: d 37.4 (q), 99.9 (s), 123.2 (d), 129.5 (d), 129.9 (d), 130.2 (d), 130.4 (d), 
140.8 (d), 141.7 (d), 143.4 (s), 145.9 (s), 148.7 (d), 165.3 (s). Anal. Calcd for C13H11IN2O 
(338.15): C, 46.18; H, 3.28; N, 8.28. Found: C, 46.30; H, 3.10; N, 8.31. 
 
      N-(2-Iodophenyl)-N-methyl-6-chloro-pyridine-3-carboxamide (4b) 
White solid, mp 114–115°C; yield 95%. IR (Nujol): 1627 cm-1. 1H NMR: d 3.38 (3H, s), 6.94–
7.02 (1H, m), 7.14–7.22 (2H, m), 7.27–7.36 (1H, m), 7.69 (1H, dd, J¼2.4, 8.2 Hz), 7.81 (1H, dd, 
J¼1.3, 8.0 Hz), 8.3 (1H, d, J¼2.4 Hz). 13C NMR: d 37.8 (q), 99.3 (s), 123.7 (d), 130.0 (d), 130.1 
(d), 130.2 (d), 130.7 (d), 139.0 (d), 140.8 (s), 146.1 (s), 149.6 (d), 152.6 (s), 167.3 (s). Anal. Calcd 
for C13H10ClIN2O (372.59): C, 41.91; H, 2.71; N, 7.52. Found: C, 42.06; H, 2.58; N, 7.61. 
 
      N-(2-Iodophenyl)-N-methyl-quinoline-3-carboxamide (4c) 
Light orange solid, mp 163–161°C; yield 97%. IR (Nujol): 1632 cm-1. 1H NMR: d 3.39 (3H, s), 
6.79–6.88 (1H, m), 7.19–7.21 (2H, m), 7.39–7.47 (1H, m), 7.59–7.72 (3H, m), 7.93 (1H, d, J¼8.6 
Hz), 8.15 (1H, d, J¼1.4 Hz), 8.82 (1H, s). 13C NMR: d 37.9 (q), 99.5 (s), 126.7 (s), 127.3 (d), 
128.7 (d), 129.0 (s), 129.3 (d), 129.9 (d), 130.0 (d), 130.2 (d), 130.3 (d), 136.9 (d), 140.6 (d), 146.4 
(s), 148.1 (s), 149.5 (d), 168.4 (s). Anal. Calcd for C17H13IN2O (388.20): C, 52.60; H, 3.38; N, 
7.22. Found: C, 52.77; H, 3.29; N, 7.29. 
 
      N-(2-Iodophenyl)-N-methyl-pyridine-4-carboxamide (10a) 
White solid, mp 80–82°C (diisopropyl ether); yield 63%. IR (Nujol): 1623 cm-1. 1H NMR: d 3.38 
(3H, s), 6.94 (1H, ddd, J¼1.8, 7.6, 8.0 Hz), 7.12 (1H, dd, J¼1.4, 7.8 Hz), 7.20–7.29 (3H, m), 7.79 
(1H, dd, J¼1.2, 8.0 Hz,), 8.39–8.46 (2H, m). 13C NMR: d 37.4 (q), 99.1 (s), 122.2 (d), 129.8 (d), 
129.9 (d), 130.1 (d), 130.2 (d), 140.5 (d), 140.7 (d), 143.4 (s), 145.9 (s), 149.7 (d), 168.4 (s). Anal. 
Calcd for C13H11IN2O (338.15): C, 46.18; H, 3.28; N, 8.28. Found: C, 46.34; H, 3.11; N, 8.21. 
 
      N-(2-Bromopyridin-3-yl)-N-methyl-pyridine-4-carboxamide (10b) 
White solid, mp 119–121°C (diisopropyl ether); yield 47%. IR (Nujol): 1623 cm-1. 1H NMR: d 
3.40 (3H, s), 7.18–7.35 (3H, m), 7.41 (1H, d, J¼7.2 Hz), 8.25 (1H, br s), 8.42–8.55 (2H, m). 13C 
NMR: d 37.4 (q), 99.8 (s), 123.2 (d), 129.7 (d), 129.9 (d), 130.3 (d), 130.6 (d), 141.5 (d), 142.7 (d), 
144.6 (s), 146.9 (s), 168.4 (s). Anal. Calcd for C12H10BrN3O (292.14): C, 49.34; H, 3.45; N, 14.38. 
Found: C, 49.49; H, 3.51; N, 14.22. 
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      N-(2-Iodophenyl)-N-methyl-2-pyridin-2-ylpropionamide (24) 
White solid, mp 82–84°C; yield 75%. IR (Nujol): 1622 cm-1. 1H NMR: d 1.50 (3H, d, J¼6.8 Hz), 
3.21 (3H, s), 3.65 (1H, q, J¼6.8 Hz), 6.72 (1H, d, J¼7.7 Hz), 7.01 (1H, dd, J¼7.5, 7.7 Hz), 7.07–
7.15 (3H, m), 7.56 (1H, dd, J¼7.6, 7.7 Hz), 7.93 (1H, d, J¼7.8 Hz), 8.41 (1H, br s). 13C NMR: d 
19.6 (q), 36.9 (d), 47.3 (q), 100.3 (s), 122.0 (d), 129.5 (d), 129.7 (d), 130.1 (d), 130.2 (d), 137.0 (d), 
140.3 (d), 145.8 (s), 149.3 (d), 161.5 (s), 173.0 (s). Anal. Calcd for C15H15IN2O (366.20): C, 49.20; 
H, 4.13; N, 7.65. Found: C, 49.34; H, 4.31; N, 7.60. 
 
General procedure for the synthesis of amides 16–18 
The acid 12, 13 or 14 (0.124 g, 1 mmol) was suspended in DME (dimethoxyethane) (8 mL), 
cooled at 0°C under nitrogen atmosphere. A solution of N-methyl-2-iodoaniline (15) (0.28 g, 
1.2 mmol) in DME (4 mL) was dropped then a solution of DMC (2-chloro-1,3-
dimethylimidazolium chloride) (0.169 g, 1 mmol) in CH2Cl2 (3 mL) and finally a solution of 
TEA (280 mL, 2 mmol) in CH2Cl2 (3 mL) was added. The reaction mixture was stirred for 1 h 
at 0°C then allowed to warm to rt and left to react overnight. The mixture was then diluted 
with 300 mL of AcOEt and washed with 30 mL of water, 30 mL of a saturated solution of 
NaHCO3, 30mL of water and 30 mL of brine. The organic layer was dried with Na2SO4 and the 
solvent evaporated under reduced pressure. The residue was chromatographed on a silica gel, 
eluent AcOEt, to give compounds 16–18. 
 
      N-(2-Iodophenyl)-N-methyl-pyridazine-4-carboxamide (16) 
Light amber-coloured solid, mp 166–168°C; yield 70%. IR (Nujol): 1636 cm-1. 1H NMR: d 3.38 
(3H, s), 6.96–7.04 (1H, m), 7.20–7.36 (3H, m), 7.75–7.79 (1H, m), 9.06 (1H, s), 9.05 (1H, s). 13C 
NMR: d 37.6 (q), 99.2 (s), 124.7 (d), 130.0 (d), 130.3 (d), 130.7 (d), 133.9 (s), 140.8 (d), 145.0 (s), 
149.5 (d), 151.1 (d), 165.8 (s). Anal. Calcd for C12H10IN3O (339.13): C, 42.50; H, 2.97; N, 12.39. 
Found: C, 42.36; H, 3.09; N, 12.22. 
 
      N-(2-Iodophenyl)-N-methyl-pyrimidine-5-carboxamide (17) 
White solid, mp 97–98°C; yield 80%. IR (Nujol): 1630 cm-1. 1H NMR: d 3.36 (3H, s), 6.92–7.00 
(1H, m), 7.21–7.36 (2H, m), 7.75–7.80 (1H, m), 8.64 (2H, s), 9.00 (1H, s). 13C NMR: d 37.7 (q), 
99.4 (s), 129.9 (s), 130.0 (d), 130.2 (d), 130.5 (d), 140.8 (d), 145.5 (s), 156.4 (2d), 159.1 (d), 165.7 
(s). Anal. Calcd for C12H10IN3O (339.13): C, 42.50; H, 2.97; N, 12.39. Found: C, 42.39; H, 3.08; 
N, 12.27. L. Basolo et al. / Tetrahedron 65 (2009) 3486–3491 3489 
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   N-(2-Iodophenyl)-N-methyl-pyrazine-2-carboxamide (18) 
Pearl grey solid, mp 94–96°C; yield 55%. IR (Nujol): 1640 cm-1. 1H NMR: d 3.42 (3H, s), 6.90–
7.01 (1H, m), 7.26–7.36 (2H, m), 7.74–7.80 (1H, m), 8.16–8.19 (1H, m), 8.40 (1H, d, J¼2.6 Hz), 
8.97 (1H, s). 13C NMR: d 37.6 (q), 99.3 (s), 129.4 (d), 129.6 (d), 130.2 (d), 139.9 (d), 142.5 (d), 
145.1 (d), 145.5 (d), 146.1 (s), 149.3 (s), 166.3 (s). Anal. Calcd for C12H10IN3O (339.13): C, 42.50; 
H, 2.97; N, 12.39. Found: C, 42.37; H, 3.09; N, 12.28. 
 
General procedure for the cyclization of amides 4, 10, 16–18 and 24 
A solution of 4a–c or 10a,b or 16–18 or 24 (1 mmol), Pd(OAc)2 (0.011 g, 0.05 mmol), AcOK 
(0.196 g, 2 mmol) and Bu4NCl (0.278 g, 1 mmol) in DMA (8 mL) was stirred at 100°C for 24 h. 
For compounds 4a–c and 16–18 the cyclization was performed by microwaves irradiation for 
45 min at 120°C at 300W. After cooling to room temperature, the mixture was diluted with 
brine (15 mL) and extracted with Et2O (3x30 mL). The organic layer was dried with Na2SO4 
and solvent evaporated under reduced pressure. The residue was chromatographed on a silica 
gel column, eluent hexane/AcOEt 2:1, to give the cyclized product. In the case of amides 4a–c 
the two regioisomers 5a–c and 6a–c were isolated, in ratio 1:3 nearly. 
 
      6-Methyl-benzo[h][1,6]naphthyridin-5-(6H)-one (5a)17 
White solid, mp 169–171°C (lit. mp 173–175°C); yield 18%. IR (Nujol): 1630 cm-1. 1H NMR: d 
3.82 (3H, s), 7.36–7.46 (2H, m), 7.51 (1H, dd, J¼4.6, 8.1 Hz), 7.60–7.69 (1H, m), 8.77 (1H, dd, 
J¼1.8, 8.1 Hz), 8.90 (1H, dd, J¼1.8, 7.9 Hz), 9.00 (1H, dd, J¼1.8, 4.6 Hz). 13C NMR: d 30.1 (q), 
114.8 (d), 120.9 (s), 123.1 (d), 123.2 (d), 125.5 (d), 129.2 (s), 131.6 (d), 137.0 (d), 139.4 (s), 150.5 
(s), 153.9 (d), 161.9 (s). Anal. Calcd for C13H10N2O (210.23): C, 74.27; H, 4.79; N, 13.33. Found: 
C, 74.39; H, 4.86; N, 13.24. 
 
      6-Methyl-benzo[c][2,7]naphthyridin-5-(6H)-one (6a)17 
White solid, mp 188–191°C (lit. mp 194–196°C); yield 62%. IR (Nujol) 1662 cm-1. 1H NMR: d 
3.80 (3H, s), 7.25–7.46 (2H, m), 7.67 (1H, dd, J¼7.6, 7.8 Hz), 8.03 (1H, d, J¼5.6 Hz), 8.27 (1H, 
d, J¼7.6 Hz), 8.88 (1H, d, J¼5.6 Hz), 9.72 (1H, s). 13C NMR: d 29.9 (q), 115.5 (d), 117.4 (s), 
123.0 (d), 124.2 (d), 129.7 (d), 130.2 (s), 131.9 (d), 136.0 (d), 139.9 (s), 140.0 (s), 140.6 (d), 168.3 
(s). Anal. Calcd for C13H10N2O (210.23): C, 74.27; H, 4.79; N, 13.32. Found: C, 74.43; H, 4.90; 
N, 13.22.  
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  2-Chloro-6-methylbenzo[h][1,6]naphthyridin-5-(6H)-one (5b) 
White solid, mp 170–172°C; yield 13%. IR (Nujol): 1625 cm-1. 1H NMR: d 3.80 (3H, s), 7.38–
7.44 (2H, m), 7.48 (1H, d, J¼8.2 Hz), 7.62–7.77 (1H, m), 8.68 (1H, d, J¼8.2 Hz), 8.81 (1H, dd, 
J¼1.3, 7.9 Hz). 13C NMR: d 30.0 (q), 114.8 (d), 115.7 (s), 119.9 (s), 123.3 (d), 124.0 (d), 125.9 (d), 
132.3 (d), 139.9 (d), 151.1 (s), 153.0 (s), 155.9 (s), 161.1 (s). Anal. Calcd  for C13H9ClN2O 
(244.68): C, 63.81; H, 3.71; N, 11.45. Found: C, 63.98; H, 3.89; N, 11.40. 
 
      2-Chloro-6-methylbenzo[c][2,7]naphthyridin-5-(6H)-one (6b) 
White solid, mp 212–214°C; yield 48%. IR (Nujol): 1635 cm-1. 1H NMR: d 3.80 (3H, s), 7.34–
7.47 (2H, m), 7.66–7.75 (1H, m), 8.07 (1H, s), 8.20 (1H, dd, J¼1.3, 8.1 Hz), 9.50 (1H, s). 13C 
NMR: d 30.0 (q), 115.4 (d), 115.8 (d), 116.5 (s), 119.6 (s), 123.3 (d), 124.4 (d), 132.9 (d), 140.1 
(s), 142.5 (s), 153.0 (d), 154.9 (s), 160.4 (s). Anal. Calcd for C13H9ClN2O (244.68): C, 63.81; H, 
3.71; N, 11.45. Found: C, 63.92; H, 3.80; N, 11.38. 
 
      5-Methyl-dibenzo[b,h][1,6]naphthyridin-6-(5H)-one (5c)18 
Light yellow solid, mp 214–216°C (lit. mp not reported); yield 16%. IR (Nujol): 1630 cm-1. 1H 
NMR: d 3.84 (3H, s), 7.39–7.47 (2H, m), 7.58–7.71 (2H, m), 7.84–7.93 (1H, m), 8.05–8.09 (1H, 
m), 8.25–8.29 (1H, m), 9.10–9.15 (1H, m), 9.35 (1H, s). 13C NMR: d 30.1 (q), 114.9 (d), 119.8 (s), 
121.3 (s), 123.2 (d), 126.1 (d), 126.9 (d), 127.5 (s), 129.4 (d), 129.6 (d), 131.8 (d), 132.3 (d), 139.0 
(d), 139.9 (s), 149.5 (s), 150.5 (s), 162.2 (s). Anal. Calcd for C17H12N2O (260.29): C, 78.44; H, 
4.65; N, 10.76. Found: C, 78.55; H, 4.64; N, 10.68. 
 
      5-Methyl-dibenzo[c,f][2,7]naphthyridin-6-(5H)-one (6c)19 
Cream solid, mp 211–213°C (lit. mp 217–218°C); yield 45%. IR (Nujol): 1639 cm-1. 1H NMR: d 
3.83 (3H, s), 7.36–7.45 (1H, m), 7.51–7.55 (1H, m), 7.66–7.75 (2H, m), 7.82–7.91 (1H, m), 8.26–
8.31 (1H, m), 8.67 (1H, d, J¼8.6 Hz), 8.79 (1H, d, J¼8.6 Hz), 9.85 (1H, s). 13C NMR: d 30.4 (q), 
115.5 (d), 118.1 (s), 118.3 (s), 122.6 (s), 122.7 (d), 127.2 (d), 127.6 (d), 129.7 (d), 130.8 (d), 130.9 
(d), 131.6 (d), 138.9 (s), 140.3 (s), 150.1 (s), 150.3 (d), 161.2 (s). Anal. Calcd for C17H12N2O 
(260.29): C, 78.44; H, 4.65; N, 10.76. Found: C, 78.29; H, 4.79; N, 10.92. 
 
      6-Methyl-6H-benzo[c][2,6]naphthyridin-5-one (11a)16 
White solid, mp 192–194°C (lit. mp 197–199°C); yield 58%. IR (Nujol): 1659 cm-1. 1H NMR: d 
3.74 (3H, s), 7.32 (1H, dd, J¼7.5, 7.8 Hz), 7.37 (1H, d, J¼7.8 Hz), 7.56 (1H, dd, J¼7.5, 8.0 Hz), 
8.19 (1H, d, J¼5.1 Hz), 8.28 (1H, d, J¼8.0 Hz), 8.75 (1H, d, J¼5.1 Hz), 9.58 (1H, s). 13C NMR: 
d 30.5 (q), 115.6 (d), 117.4 (s), 117.5 (s), 121.0 (d), 123.0 (d), 123.5 (d), 128.0 (s), 130.8 (d), 138.5 
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(s), 145.8 (d), 148.3 (d), 160.5 (s). Anal. Calcd for C13H10N2O (210.24): C, 74.27; H, 4.79; N, 
13.32. Found: C, 74.39; H, 4.87; N, 13.43. 
 
      6-Methyl-6H-pyrido[2,3-f][2,6]naphthyridin-5-one (11b) 
White solid, mp 215–218°C (diisopropyl ether); yield 69%. IR (Nujol): 1630 cm-1. 1H NMR: d 
3.81 (3H, s), 7.54 (1H, dd, J¼4.4, 8.5 Hz), 7.74 (1H, d, J¼8.5 Hz), 8.26 (1H, d, J¼5.1 Hz), 8.66 
(1H, d, J¼4.4 Hz), 8.93 (1H, d, J¼5.1 Hz), 10.18 (1H, s). 13C NMR: d 30.1 (q), 120.5 (d), 122.4 
(d), 124.8 (d), 128.7 (s), 132.3 (s), 134.8 (s), 136.4 (s), 144.8 (d), 148.2 (d), 150.1 (d), 160.3 (s). 
Anal. Calcd for C12H9N3O (211.22): C, 68.24; H, 4.29; N, 19.89. Found: C, 68.39; H, 4.11; N, 
19.96. 
 
      6-Methyl-pyridazino[4,5-c]quinolin-5-(6H)-one (19a) 
Cream solid, mp 250–252°C; yield 28%. IR (Nujol): 1626 cm-1. 1H NMR: d 3.85 (3H, s), 7.44–
7.55 (2H, m), 7.74–7.83 (1H, m), 8.39–8.44 (1H, m), 10.01 (1H, d, J¼1.2 Hz), 10.10 (1H, d, 
J¼1.2 Hz). 13C NMR: d 30.5 (q), 114.8 (s), 115.9 (d), 120.0 (s), 123.9 (d), 124.0 (d), 129.8 (s), 
133.5 (d), 140.8 (s), 145.9 (d), 149.2 (d), 159.3 (s). Anal. Calcd for C12H9N3O (211.22): C, 68.24; 
H, 4.29; N, 19.89. Found: C, 68.37; H, 4.33; N, 19.75. 
 
      6-Methyl-pyridazino[4,3-c]quinolin-5-(6H)-one (19b) 
Light yellow solid, mp 200–202°C; yield 24%. IR (Nujol): 1630 cm-1. 1H NMR: d 3.83 (3H, s), 
7.45–7.53 (2H, m), 7.70–7.78 (1H, m), 8.39 (1H, d, J¼5.3 Hz), 9.20–9.25 (1H, m), 9.55 (1H, d, 
J¼5.3 Hz). 13C NMR: d 30.4 (q), 115.1 (d), 118.3 (s), 121.5 (s), 124.0 (d), 124.2 (d), 125.5 (d), 
132.8 (d), 139.4 (s), 150.6 (d), 151.0 (s), 160.6 (s). Anal. Calcd for C12H9N3O (211.22): C, 68.24; 
H, 4.29; N, 19.89. Found: C, 68.33; H, 4.36; N, 19.80. 
 
      6-Methyl-pyrimido[5,4-c]quinolin-5-(6H)-one (20) 
White solid, mp 190–192°C; yield 79%. IR (Nujol): 1628 cm-1. 1H NMR: d 3.36 (3H, s), 6.92–
7.00 (1H, m), 7.21–7.36 (2H, m), 7.75–7.80 (1H, m), 8.64 (1H, s), 9.00 (1H, s). 13C NMR: d 29.9 
(q), 115.0 (d), 117.9 (s), 118.8 (s), 123.4 (d), 125.9 (d), 133.9 (d), 141.1 (s), 155.9 (s), 159.4 
(d), 160.4 (s), 160.9 (d). Anal. Calcd for C12H9N3O (211.22): C, 68.24; H, 4.29; N, 19.89. Found: 
C, 68.35; H, 4.35; N, 19.77. 3490 L. Basolo et al. / Tetrahedron 65 (2009) 3486–3491 
 
      4.12  6-Methyl-pyrazino[2,3-c]quinolin-5-(6H)-one (21) 
Ivory-coloured solid, mp 195–197°C; yield 49%. IR (Nujol): 1633 cm-1. 1H NMR: d 3.88 (3H, s), 
7.39–7.49 (2H, m), 7.67–7.75 (1H, m), 8.84 (1H, dd, J¼1.6, 7.9 Hz), 8.91–8.97 (2H, m,). 13C 
NMR: d 30.7 (q), 115.0 (d), 119.3 (s), 119.6 (s), 123.5 (d), 125.8 (d), 132.6 (d), 136.8 (s), 139.3 (s), 
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145.5 (d), 148.3 (d), 160.7 (s). Anal. Calcd for C12H9N3O (211.22): C, 68.24; H, 4.29; N,19.89. 
Found: C, 68.40; H, 4.38; N, 19.83. 
 
      5,7-Dimethyl-5H,6H,7H-pyrido[2,3-d][1]benzazepin-6-one (25) 
White solid, mp 162–164°C; yield 90%. IR (Nujol): 1632 cm-1. 1H NMR: d 1.70 (3H, d, J¼6.7 
Hz), 3.37 (3H, s), 3.60 (1H, q, J¼6.7 Hz), 7.33–7.37 (2H, m), 7.41 (1H, d, J¼8.0 Hz), 7.49–7.56 
(2H, m), 7.88 (1H, d, J¼7.6 Hz), 8.68 (1H, d, J¼4.7 Hz). 13C NMR: d 11.7 (q), 36.7 (d), 43.2 (q), 
122.6 (d), 123.0 (d), 125.7 (d), 129.6 (d), 130.1 (d), 132.0 (s), 132.1 (s),135.8 (d),142.0 (s),149.5 
(d),156.1 (s),172.4 (s). Anal. Calcd for C15H14N2O (238.29): C, 75.61; H, 5.92; N, 11.76. Found: 
C, 75.54; H, 5.81; N, 11.60. 
 
CHAPTER 2 
General procedure for the synthesis of N-aryl indolines 
      Procedure 1 (solvent, thermal heating) 
The base was suspended in toluene in an oven dried round bottom flask, the suspension was 
flushed with nitrogen for 10 minutes, then aryl chloride, palladium precatalyst, ligand and 
indoline were added in this exact order. A further 5 minutes nitrogen was flushed, then the 
reaction mixture was refluxed for 24 hours. After this time the suspension was cooled to room 
temperature, added of  ethyl acetate and filtered over celite®. The resulting solution was 
washed three times with brine, dried with sodium sulphate and filtered; solvent was 
evaporated under reduced pressure. The residue was purified by flash column 
chromatography using hexane/ethyl acetate (4/1) as eluent.     
      Procedure 2 (solvent-free, microwave heating) 
A round bottom flask was charged with palladium precatalyst and the aryl halide. Then 3 
grams of finely powdered K2CO3 was added. At this point the ligand was added on the 
resulting surface of K2CO3 and a solution of indoline in 10 ml CH2Cl2 was used to dissolve 
reactant and suspend K2CO3. The CH2Cl2 was then removed under reduced pressure and 
recovered for use in the following reaction. The residual powder was diluted with 1 gram of 
K2CO3 and grinded with mortar and pestle for 5 minutes. Microwave oven reactor was charged 
with reactant powder which was compacted as much as possible. After microwave heating to 
140°C for 20 minutes at a medium of 350 W, a flash silica gel column was charged with the 
powder and eluted with hexane/ethyl acetate (4/1) to recover purified product. 
Note: the only exception for procedure 2 was the case of indoline-2-carboxylic acid. It needs an 
elaboration before column chromatography and a special care for the column itself: in fact, 
after microwave heating, the powder was dissolved in water and extracted with Et2O to 
remove non acidic compound (mainly unreacted aryl halide), then the basic water was 
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acidified to pH 3 and extracted three times with ethyl acetate. The combined organic layer was 
dried over sodium sulphate, filtered and solvent was removed under reduced pressure. The 
residue was purified by a short column chromatography flushed with nitrogen during the 
elution made by ethyl acetate/methanol (20/1). 
Procedure C (solvent&ligand-free, microwave heating)  
A round bottom flask was charged with indoline followed by 1 gram of finely grinded K2CO3, 
and then by the aryl halide. A finely grinded mix of 1 gram of K2CO3  with Pd2(dba)3 was 
prepared and suspended in 10 ml CH2Cl2. The suspension was added in the round bottom 
flask and the CH2Cl2 was immediately removed under reduced pressure and recovered for use 
in the following reaction. The residual powder was diluted with 1 gram of K2CO3 and grinded 
with mortar and pestle for 5 minutes. Microwave oven reactor was charged with reactant 
powder which was compacted as much as possible (4-5 minutes of beats over semirigid 
surface). After microwave heating to 140°C for 30 minutes at a medium of 400 W, a flash silica 
gel column was charged with the powder and eluted with hexane/ethyl acetate (4/1) to recover 
purified product. 
Note: the only exception for procedure C was the case of indoline-2-carboxylic acid as for 
procedure B. See above. 
     1-(4’-nitrophenyl)indoline 29   
1H NMR (200 MHz, CDCl3, 20°C, TMS): δ=8.18-8.26 (m, 2H), 7.15-7.36 (m, 5H), 6.83 (ddd, 
J=0.9, 7.3, 8.4 Hz, 1H), 4.07 (t, J=8.3 Hz, 2H), 3.21 (t, J=8.3 Hz, 2H). 13C NMR (200 MHz, 
CDCl3): δ=149.4 (s), 144.5 (s), 139.9 (s), 132.7 (s), 127.5 (d), 125.9 (d, 2C), 125.8 (d), 121.9 (d), 
115.0 (d, 2C), 110.8 (d), 52.3 (t), 28.2 (t). IR (KBr): ν¯=1294 cm−1 (Aromatic C-N). MS (ESI) m/z 
(%): 241.3 (100) [M+H]. Elemental analysis: calcd (%) for C14H12N2O2 (240.3): C 69.99, H 5.03, 
N 11.66; found: C 69.89, H 5.09, N 11.62.  
 
      4-(indolin-1-yl)benzonitrile 3063  
1H NMR (200 MHz, CDCl3, 20°C, TMS): δ=7.56-7.60 (m, 2H), 7.10-7.29 (m, 5H), 6.88 (ddd, 
J=1.1, 7.14, 8.2 Hz, 1H), 4.00 (t, J=8.3 Hz, 2H), 3.18 (t, J=8.3 Hz, 2H). 13C NMR (200 MHz, 
CDCl3, 20°C, TMS): δ=147.5 (s), 144.9 (s), 133.8 (d), 132.4 (s), 127.4 (d), 125.8 (d, 2C), 121.3 (d), 
120.1 (d), 116.1 (d, 2C), 110.1 (d), 101.1 (s), 52.0 (t), 28.2 (t). 
 
      Methyl 4-(indolin-1-yl)benzoate 28 
1H NMR (200 MHz, CDCl3, 20°C, TMS): δ= 7.98-8.05 (m, 2H), 7.10-7.31 (m, 5H), 6.85 (ddd, 
J=0.9, 7.5, 8.2 Hz, 1H), 4.00 (t, J=8.4 Hz, 2H), 3.91 (s, 3H), 3.15 (t, J=8.4 Hz, 2H). 13C NMR 
(200 MHz, CDCl3, 20°C, TMS): δ=167.1 (s), 148.1 (s), 145.6 (s), 132.1 (s), 131.3 (s), 127.4 (d), 
125.5 (d, 2C), 121.4 (s), 120.6 (d), 115.6 (d, 2C), 109.9 (d), 52.0 (t), 51.9 (q), 28.3 (t). IR (KBr): 
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ν¯=1321 cm−1 (Aromatic C-N). MS (ESI) m/z (%): 254.1 (100) [M+H]. Elemental analysis: calcd 
(%) for C16H15NO2 (253.1): C 75.87, H 5.97, N 5.53; found: C 75.61, H 6.10, N 5.50. 
 
      2-methyl-1-(4-nitrophenyl)indoline 35 
1H NMR (200 MHz, CDCl3, 20°C, TMS): δ= 8.15-8.23 (m, 2H), 7.15-7.31 (m, 5H), 6.91-6.99 (m, 
1H), 4.44-4.59 (m, 1H), 3.40-3.52 (dd, J=8.6, 15.6 Hz, 1H), 2.69 (dd, J=2.7, 15.6 Hz, 1H), 1.37-
1.40 (d, J=6.2 Hz, 3H). 13C NMR (200 MHz, CDCl3, 20°C, TMS): δ=149.1 (s), 143.7 (s), 140.1 
(s), 131.6 (s), 127.5 (d), 126.1 (d, 2C), 126.0 (d), 122.1 (d), 115.2 (d, 2C), 112.2 (d), 59.9 (d), 37.0 
(t), 20.2(q). IR (KBr): ν¯=1294 cm−1 (Aromatic C-N). MS (ESI) m/z (%): 255.2 (100) [M+H]. 
Elemental analysis: calcd (%) for C15H14N2O2 (254.3): C 70.85, H 5.55, N 11.02; found: C 70.77, 
H 5.88, N 11.00. 
 
      1-(4-methylpyridin-2-yl)indoline 2764  
1H NMR (200 MHz, CDCl3, 20°C, TMS): δ=8.12-8.22 (m, 2H), 7.14-7.21 (m, 2H), 6.85 (ddd, 
J=1.1, 7.3, 8.4 Hz, 1H), 6.60-6.63 (m, 2H br), 4.05 (t, J=8.6 Hz, 2H), 3.20 (t, J=8.6 Hz, 2H), 2.31 
(s, 3H). 13C NMR (200 MHz, CDCl3, 20°C, TMS): δ=155.6 (s), 148.0 (s), 147.5 (s), 144.9 (s), 
131.2 (s), 127.1 (d), 124.4 (d), 120.1 (d), 115.8 (d), 113.2 (d), 108.9 (d), 49.4 (t), 27.8 (t), 21.5 (q). 
 
      1-(pyridin-2-yl)indoline 2665   
1H NMR (200 MHz, CDCl3, 20°C, TMS): δ=8.33 (m, 1H), 8.16-8.20 (m, 1H), 7.14-7.20 (m, 2H), 
7.57 (m, 1H), 6.85 (ddd, J=1.0, 7.3, 7.6 Hz, 1H), 6.71-6.79 (m, 2H), 4.03 (t, J=8.6 Hz, 2H), 3.20 
(t, J=8.6 Hz, 2H). 13C NMR (200 MHz, CDCl3, 20°C, TMS): δ=155.3 (s), 147.8 (s), 144.9 (s), 
137.1 (d), 131.2 (s), 127.1 (d), 124.4 (d), 120.3 (d), 114.3 (d), 113.2 (d), 108.6 (d), 49.4 (t), 27.8 
(t). 
  
      1-phenylindoline66  
1H NMR (200 MHz, CDCl3, 20°C, TMS): δ=7.30-7.34 (m, 2H), 7.19-7.23 (m, 2H), 7.04-7.16 (m, 
3H), 6.90-6.97 (m, 1H), 6.71-6.75 (m, 1H), 3.92 (t, J=8.4 Hz, 2H), 3.10 (t, J=8.4 Hz, 2H). 13C 
NMR (200 MHz, CDCl3, 20°C, TMS): δ=147.1 (s), 144.2 (s), 131.2 (s), 129.2 (d, 2C), 127.1 (d), 
125.0 (d), 120.9 (d), 118.8 (d, 2C), 117.7 (d), 108.2 (d), 52.1 (t), 28.2 (t). 
 
      2-methyl-1-phenylindoline 34 
1H NMR (200 MHz, CDCl3, 20°C, TMS): δ=7.58-7.63 (m, 2H), 7.24-7.49 (m, 4H), 6.99-7.12 (m, 
2H), 6.69-6.80 (m, 1H), 4.30-4.47 (m, 1H), 3.33 (dd, J=8.8, 15.6 Hz, 1H), 2.76 (dd, J=7.5, 15.6 
Hz, 1H), 1.33 (d, J=6.2 Hz, 3H). 13C NMR (200 MHz, CDCl3, 20°C, TMS): δ=148.9 (s), 141.5 (s), 
129.7 (s), 129.4 (d, 2C), 128.9 (d), 125.0 (d), 123.1 (d), 122.0 (d, 2C), 118.9 (d), 108.6 (d), 60.2 
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(d), 37.4 (t), 20.2 (q). IR (KBr): ν¯=1311 cm−1 (Aromatic C-N). MS (ESI) m/z (%): 210.2 (100) 
[M+H]. Elemental analysis: calcd (%) for C15H15N (209.3): C 86.08, H 7.22, N 6.69; found: C 
86.23, H 7.58, N 6.50. 
 
      (S)-1-(4-nitrophenyl)indoline-2-carboxylic acid 36 
1H NMR (200 MHz, MeOD, 20°C, TMS): δ=8.20 (d, J=8.9 Hz, 2H), 7.19-7.41 (m, 5H), 6.97 (dd, 
J=1.1, 7.3 Hz, 1H ), 4.85 (dd J=2.9, 10.6 Hz, 1H), 3.69 (dd J=10.6, 16.1 Hz, 1H ), 3.31 (dd 
J=2.9, 16.1 Hz, 1H). 13C NMR (200 MHz, CDCl3, 20°C, TMS): δ=175.9 (s), 148.9 (s), 144.2 (s), 
141.0 (s), 129.9 (s), 127.9 (d), 125.9 (2C, d), 125.6 (d), 122.5 (s), 115.7 (2C, d), 111.9 (d), 65.0 (d), 
33.8 (t). IR (KBr): ν¯=1299 cm−1 (Aromatic C-N). MS (ESI-) m/z (%): 283.1 (100) [M+-H]. 
Elemental analysis: calcd (%) for C15H12N2O4 (284.3): C 63.38, H 4.25, N 9.85; found: C 63.45, 
H 4.58, N 9.79. [α]D20=−40.4 (c=0.02 in CHCl3). 
 
      1-(4-nitrophenyl)indoline-2-carboxylate 37 
1H NMR (200 MHz, CDCl3, 20°C, TMS): δ= 8.17-8.22 (m, 2H), 7.18-7.37 (m, 5H), 6.92-6.99 (m, 
1H), 4.85 (dd, J=3.5, 10.4 Hz, 1H), 3.76 (s, 3H), 3.64 (dd, J=10.4, 16.1 Hz, 1H),  3.26 (dd J=3.5, 
16.1 Hz, 1H). 13C NMR (200 MHz, CDCl3, 20°C, TMS): δ=165.2 (s), 148.9 (s), 144.3 (s), 133.0 
(s), 129.9 (s), 127.9 (d), 125.9 (2C, d), 125.6 (d), 122.4 (d), 115.7 (2C, d), 111.8 (d), 65.3 (d), 52.9 
(q), 33.8 (t). IR (KBr): ν¯=1313 cm−1 (Aromatic C-N). MS (ESI-) m/z (%): 297.1 (100) [M+-H]. 
Elemental analysis: calcd (%) for C16H14N2O4 (284.3): C 64.42, H 4.73, N 9.39; found: C 64.54, 
H 4.84, N 9.12. 
 
      1-(4-methoxyphenyl)indoline 31 
1H NMR (200 MHz, CDCl3, 20°C, TMS): δ= 7.10-7.24 (m, 3H), 7.03-7.07 (m, 1H), 6.91-6.98 (m, 
3H), 6.69-6.77 (m, 1H), 3.89 (t, J=8.2 Hz, 2H), 3.83 (s, 3H), 3.13 (t, J=8.2 Hz, 2H). 13C NMR 
(200 MHz, CDCl3, 20°C, TMS): δ=155.2 (s), 148.9 (s), 138.3 (s), 130.9 (s), 127.3 (d), 125.1 (d), 
121.1 (d, 2C), 118.4 (d), 114.9 (d, 2C), 107.7 (d), 55.8 (q), 53.4 (t), 28.6 (t). IR (KBr): ν¯=1248 
cm−1 (Aromatic C-N). MS (ESI) m/z (%): 226.2 (100) [M+H]. Elemental analysis: calcd (%) for 
C15H15NO (225.3): C 79.97, H 6.71, N 6.22; found: C 80.02, H 6.91, N 6.02. 
 
      1-(2-(1,3-dioxolan-2-yl)-4-nitrophenyl)indoline 38 
1H NMR (200 MHz, CDCl3, 20°C, TMS): δ=8.59 (s, 1H), 8.19 (d, J=8.9 Hz, 1H), 7.47 (d, J=8.9, 
1H), 7.23 (d, J=6.8 Hz, 1H), 7.04-7.11 (m, 1H), 6.81-6.88 (m, 1H), 6.67 (d,  J=7.3 Hz, 1H), 3.93-
4.24 (m, 6H), 6.06 (s, 1H), 3.18 (t, J=8.4 Hz, 2H). 13C NMR (200 MHz, CDCl3, 20°C, TMS): 
δ=151.1 (s), 148.7 (s), 144.4 (s),  134.4 (s), 131.6 (s), 127.5 (d), 125.8 (d), 125.4 (d), 124.8 (d), 
123.0 (d), 120.8 (d), 110.5 (d), 99.3 (d), 65.8 (t, 2C), 56.6 (t), 29.3 (t). IR (KBr): ν¯=1337 cm−1 
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(Aromatic C-N). MS (ESI) m/z (%): 313.0 (100) [M+H]. Elemental analysis: calcd (%) for 
C17H16N2O4 (312.3): C 65.38, H 5.16, N 8.97; found: C 65.47, H 5.22, N 8.86. 
 
      1-(2-(1,3-dioxolan-2-yl)-4-fluorophenyl)indoline 33 
1H NMR (200 MHz, CDCl3, 20°C, TMS): δ=7.25-7.40 (m, 2H), 6.96-7.18 (m, 3H), 6.72 (ddd, 
J=0.9, 7.3, 8.2 Hz, 1H), 6.28 (1H, d,  J=7.3 Hz, 1H), 6.08 (d, J=1.6 Hz, 1H), 3.64-4.20 (m br, 
6H), 3.14 (t, J=8.2 Hz, 2H). 13C NMR (200 MHz, CDCl3, 20°C, TMS): δ=161.1 (d, J=246 Hz), 
151.9 (s), 141.3 (d, J=3.0 Hz), 138.7 (d, J=8.0 Hz), 130.4 (s), 127.6 (d, J=8.1 Hz), 127.5 (d), 
124.8 (d), 118.8 (d), 118.0 (d,  J=23.8 Hz), 114.4 (d, J=23.8 Hz),  108.9 (d), 99.65 (d, J=1.3 Hz), 
65.7 (t, 2C), 57.4 (t), 29.2 (t). IR (KBr): ν¯=1301 cm−1 (Aromatic C-N). MS (ESI) m/z (%): 286.1 
(100) [M+H]. Elemental analysis: calcd (%) for C17H16FNO2 (285.3): C 71.56, H 5.65, N 4.91; 
found: C 71.52, H 5.70, N 4.83. 
 
      3-(1,3-dioxolan-2-yl)-2-(indolin-1-yl)quinoline 39 
1H NMR (200 MHz, CDCl3, 20°C, TMS): δ=8.46 (s, 1H), 7.79-7.91 (m, 2H), 7.60-7.69 (ddd, 
J=1.3, 7.0, 8.5 Hz, 1H), 7.39-7.47 (m, 1H), 7.21 (d, J=7.3 Hz, 1H), 7.02-7.10 (m, 1H),  6.78-6.94 
(m, 2H), 6.11 (s, 1H), 3.98-4.25 (m, 6H), 3.13-3.22 (t, J=8.5 Hz, 2H), 13C NMR (200 MHz, 
CDCl3, 20°C, TMS): δ=154.7 (s), 148.8 (s), 148.2 (s), 137.8 (d), 131.7 (s), 130.5 (s), 128.2 (d), 
128.1 (d), 127.1 (d), 127.0 (s), 126.4 (s), 125.5 (d), 125.1 (d), 120.6 (d), 110.8 (d), 100.2 (d), 65.7 
(t, 2C), 53.6 (t), 29.1 (t). IR (KBr): ν¯=1262 cm−1 (Aromatic C-N). MS (ESI) m/z (%): 319.2 (100) 
[M+H]. Elemental analysis: calcd (%) for C20H18N2O2 (318.4): C 75.45, H 5.70, N 8.80; found: C 
75.52, H 5.80, N 8.73. 
N-methyl-4-nitro-N-phenylaniline 40 see Urgaonkar et al., J. Org. Chem. 2004, 69, 9135-
9142  
4-methyl-N-(4-nitrophenyl)aniline 41 see Buchwald et al. J. AM. CHEM. SOC. 2009, 131, 
17423–17429  
1-(4-nitrophenyl)-1H-indole 46  see Mino et al. SYNLETT 2008, 4, 614–620 
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CHAPTER 3 
General Procedure for the Synthesis of Compounds 49 
A solution of (2R,5S)-48 (2.55 mmol) in TFA (6 mL) was stirred at room temperature for 3 h. 
The solvent was then evaporated under reduced pressure and the residue purified by column 
chromatography using light petroleum ether/AcOEt (4:1) as eluent. 
 
      (2S,5S)-3,5-Dimethyl-2-(1-phenylvinyl)imidazolidin-4-one (49a) 
Yield 93%; pale-yellow oil. [α]D 25 = +27.5 (c = 0.37, CHCl3). IR (Nujol): ν˜ = 1670, 3430 cm–1. 
1H NMR (400 MHz, CDCl3): δ = 1.38 (d, J = 7.1 Hz, 3 H), 3.04 (s, 3 H), 4.08 (q, J = 7.1 Hz, 1 H), 
5.71 (s, 1 H), 5.72 (s, 1 H), 5.89 (s, 1 H), 6.57 (br. s, 1 H), 7.28–7.30 (m, 2 H), 7.42–7.48 (m, 3 H) 
ppm. 13C NMR (100 MHz, CDCl3, 25 °C): δ = 14.7 (q), 28.1 (q), 54.1 (d), 74.2 (d), 122.9 (t), 126.9 
(d), 129.2 (d), 129.8 (d), 134.5 (s), 139.5 (s), 169.3 (s) ppm. MS: m/z = 216 [M]+. C13H16N2O 
(216.28): calcd. C 72.19, H 7.46, N 12.95; found C 72.26, H 7.38, N 12.86. 
 
      (2S,5S)-5-Isopropyl-3-methyl-2-(1-phenylvinyl)imidazolidin-4-one (49b) 
Yield 95 %; cream crystals; m.p. 93°C (iPr2O). [α]D 25 = +22.5 (c = 0.45, CHCl3). IR (Nujol): ν˜ 
= 1664, 3428 cm–1. 1H NMR (400 MHz, CDCl3, 25 °C): δ = 0.87 (d, J = 7.0 Hz, 3 H), 1.00 (d, J 
= 7.1 Hz, 3 H), 2.39 (dqq, J = 3.9, 7.0, 7.1 Hz, 1 H), 3.05 (s, 3 H), 4.19 (d, J = 3.9 Hz, 1 H), 5.74 
(s, 1 H), 5.87 (s, 1 H), 5.98 (s, 1 H), 7.28–7.32 (m, 2 H), 7.41–7.50 (m, 3 H), 11.07 (br. s, 1 H) 
ppm. 13C NMR (100 MHz, CDCl3, 25 °C): δ = 16.4 (q), 18.2 (q), 28.1 (d), 28.9 (q), 60.1 (d), 74.6 
(d), 124.7 (t), 127.5 (d), 129.9 (d), 130.7 (d), 133.6 (s), 139.3 (s), 168.6 (s) ppm. MS: m/z = 244 
[M]+. C15H20N2O (244.33): calcd. C 73.74, H 8.25, N 11.47; found C 73.82, H 8.09, N 11.25. 
 
      (2S,5S)-5-Benzyl-3-methyl-2-(1-phenylvinyl)imidazolidin-4-one (49c) 
Yield 93%; white crystals; m.p. 91°C (iPr2O). [α]D 25 = –30.3 (c = 0.27, CHCl3). IR (Nujol): ν˜ = 
1682, 3444 cm– 1. 1H NMR (400 MHz, CDCl3, 25 °C): δ = 2.86 (s, 3 H), 3.13–3.20 (m, 2 H), 
4.14–4.18 (m, 1 H), 5.14 (s, 1 H), 5.38 (s, 1 H), 5.54 (s, 1 H), 5.75 (br. s, 1 H), 7.08–7.36 (m, 10 
H) ppm. 13C NMR (100 MHz, CDCl3, 25 °C): δ = 28.8 (d), 34.3 (t), 59.3 (q), 74.9 (d), 124.1 (t), 
127.3 (d), 129.2 (d), 129.8 (d), 129.9 (d), 130.2 (d), 130.4 (d), 132.1 (s), 134.0 (s), 139.6 (s), 168.4 
(s) ppm. MS: m/z = 292 [M]+. C19H20N2O (292.37): calcd. C 78.05, H 6.89, N 9.58; found C 77.93, 
H 7.02, N 9.74. 
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General Procedure for the Synthesis of Compounds 51 
TEA (0.51 mL, 3.64 mmol) was added to a solution of  49 (0.7 mmol) in dry CH2Cl2 (3 mL). The 
mixture was cooled to 0 °C and a solution of 50 in dry CH2Cl2 (2 mL) was added dropwise 
whilst stirring. After 24 h at room temperature the mixture was washed with 5% HCl (30 mL) 
and with aq. NaHCO3 (30 mL) and then the organic layer was dried with Na2SO4. The solvent 
was evaporated and the crude mixture was purified by silica gel column chromatography with 
light petroleum ether/AcOEt (1:1) as eluent to give 51. 
 
      (2R,5S)-3,5-Dimethyl-1-(2-nitrobenzoyl)-2-(1-phenylvinyl)imidazolidin-4-one (51a) 
Yield 51% (as a mixture of two conformers in a ratio of 2:1); pale-yellow crystals; m.p. 160°C 
(iPr2O). [α]D 25 = –10.2 (c = 0.10, CHCl3). IR (Nujol): ν˜ = 1652, 1704 cm–1. Major conformer: 
1H NMR (400 MHz, CDCl3, 25°C): δ = 0.41 (d, J = 6.9 Hz, 3 H), 3.04 (s, 3 H), 3.78 (q, J = 6.9 
Hz, 1 H), 5.56 (s, 1 H), 5.77 (s, 1 H), 6.06 (s, 1 H), 6.98–8.26 (m, 9 H) ppm. 13C NMR 
(100 MHz, CDCl3, 25°C): δ = 18.2 (q), 27.5 (q), 55.6 (d), 79.2 (d), 122.3 (t), 124.9 (d), 128.0 (d), 
128.8 (d), 129.0 (d), 129.4 (d), 131.0 (d), 132.0 (s), 134.8 (d), 138.1 (s), 144.4 (s), 144.8 (s), 167.5 
(s), 170.2 (s) ppm. Minor conformer: 1H NMR (400 MHz, CDCl3, 25°C): δ = 1.22 (d, J = 6.9 Hz, 
3 H), 2.84 (s, 3 H), 4.65 (q, J = 6.9 Hz, 1 H), 4.69 (s, 1 H), 5.13 (s, 1 H), 5.31 (s, 1 H), 6.98–8.26 
(m, 9 H) ppm. 13C NMR (100 MHz, CDCl3, 25°C): δ = 16.9 (q), 27.4 (q), 55.8 (d), 80.1 (d), 122.4 
(t), 125.2 (d), 128.0 (d), 128.9 (d), 129.2 (d), 129.7 (d), 130.5 (d), 132.2 (s), 134.8 (d), 136.8 (s), 
144.4 (s), 144.9 (s), 167.5 (s), 170.9 (s) ppm. MS: m/z = 365 [M]+. C20H19N3O4 (365.38): calcd. C 
65.74, H 5.24, N 11.50; found C 65.98, H 5.09, N 11.44. 
 
      (2R,5S)-1-(5-Chloro-2-nitrobenzoyl)-3,5-dimethyl-2-(1-phenylvinyl)-        
imidazolidin-4-one (51aa) 
Yield 55% (as a mixture of two conformers in a ratio of 1.25:1); pale-yellow crystals; m.p. 62°C 
(iPr2O). [α]D 25 = –13.5 (c = 26.7, CHCl3). IR (Nujol): ν˜ = 1640, 1690 cm–1. Major conformer: 
1H NMR (400 MHz, CDCl3, 25°C): δ = 0.40 (d, J = 6.8 Hz, 3 H), 2.97 (s, 3 H), 3.74 (q, J = 6.8 
Hz, 1 H), 5.50 (s, 1 H), 5.70 (s, 1 H), 5.98 (s, 1 H), 6.97–8.12 (m, 8 H) ppm. 13C NMR (100 MHz, 
CDCl3, 25°C): δ = 17.8 (q), 27.1 (q), 55.0 (d), 78.6 (d), 121.8 (t), 126.0 (d), 126.4 (d), 127.3 (d), 
128.4 (d), 128.7 (d), 130.6 (d), 133.0 (s), 137.5 (s), 141.1 (s), 142.8 (s), 143.8 (s), 165.3 (s), 169.4 
(s) ppm. Minor conformer: 1H NMR (400 MHz, CDCl3, 25°C): δ = 1.21 (d, J = 6.5 Hz, 3 H), 2.81 
(s, 3 H), 4.57 (q, J = 6.5 Hz, 1 H), 4.75 (s, 1 H), 5.20 (s, 1 H), 5.32 (s, 1 H), 6.98–8.12 (m, 8 H) 
ppm. 13C NMR (100 MHz, CDCl3, 25°C): δ = 16.4 (q), 26.9 (q), 55.3 (d), 79.4 (d), 122.1 (t), 126.0 
(d), 126.4 (d), 127.3 (d), 128.5 (d), 128.9 (d), 130.6 (d), 133.1 (s), 136.2 (s), 141.1 (s), 142.7 (s), 
144.2 (s), 165.3 (s), 170.1 (s) ppm. MS: m/z = 399 [M]+. C20H18ClN3O4 (399.83): calcd. C 60.08, H 
4.54, N 10.51; found C 60.20, H 4.31, N 10.73. 
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      (2R,5S)-1-(5-Fluoro-2-nitrobenzoyl)-3,5-dimethyl-2-(1-phenylvinyl)-  
            imidazolidin-4-one (51ab) 
Yield 60% (as a mixture of two conformers, in a ratio of 2:1); yellow oil. [α]D 25 = –4.9 (c = 5.2, 
CHCl3). IR (Nujol): ν˜ = 1638, 1702 cm–1. Major conformer: 1H NMR (400 MHz, CDCl3, 25°C): 
δ = 0.45 (d, J = 6.9 Hz, 3 H), 3.04 (s, 3 H), 3.77 (q, J = 6.9 Hz, 1 H), 5.57 (s, 1 H), 5.76 (s, 1 H), 
6.03 (s, 1 H), 6.86–8.30 (m, 8 H) ppm. 13C NMR (100 MHz, CDCl3, 25°C): δ = 17.8 (q), 27.0 (q), 
54.9 (d), 78.6 (d), 116.7 (dd, 2JC-F = 23.2 Hz), 117.6 (dd, 2JC-F = 23.0 Hz), 121.8 (t), 127.4 (d), 
128.0 (dd, 3JC-F = 9.9 Hz), 128.4 (d), 128.7 (d), 134.4 (d, 3JC-F = 8.0 Hz), 137.5 (s), 140.7 (s), 
143.8 (s), 165.2 (d, 1JC-F = 259.6 Hz), 169.4 (s), 170.1 (s) ppm. Minor conformer: 1H NMR (400 
MHz, CDCl3, 25 °C): δ = 1.27 (d, J = 6.9 Hz, 3 H), 2.86 (s, 3 H), 4.64 (q, J = 6.9 Hz, 1 H), 4.80 
(s, 1 H), 5.25 (s, 1 H), 5.33 (s, 1 H), 6.86–8.30 (m, 8 H) ppm. 13C NMR (100 MHz, CDCl3, 25 °C): 
δ = 16.4 (q), 26.9 (q), 55.3 (d), 79.2 (d), 115.9 (dd, 2JC-F = 23.4 Hz), 117.5 (dd, 2JC-F = 22.9 
Hz), 122.0 (t), 127.3 (d), 127.7 (dd, 3JC-F = 9.7 Hz), 128.4 (d), 128.8 (d), 134.5 (d, 3JC-F = 8.0 
Hz), 136.3 (s), 140.6 (s), 144.4 (s), 165.4 (d, 1JC-F = 260.2 Hz), 169.3 (s), 169.9 (s) ppm. MS: 
m/z = 383 [M]+. C20H18FN3O4 (383.37): calcd. C 62.66, H 4.73, N 10.96; found C 62.88, H 4.56, 
N 11.07. 
 
      (2R,5S)-5-Isopropyl-3-methyl-1-(2-nitrobenzoyl)-2-(1-phenylvinyl)- 
             imidazolidin-4-one (51b) 
Yield 75% (as a mixture of two conformers in, a ratio of 3:1); yellow oil. [α]D 25 = –18.3 (c = 
0.21, CHCl3). IR (Nujol): ν˜ = 1665, 1688 cm–1. Major conformer: 1H NMR (400 MHz, CDCl3, 
25°C): δ = 0.92 (d, J = 5.9 Hz, 3 H), 1.11 (d, J = 6.6 Hz, 3 H), 1.44 (dqq, J = 5.9, 6.6, 9.2 Hz, 1 
H), 2.84 (s, 3 H), 4.40 (d, J = 9.2 Hz, 1 H), 4.86 (s, 1 H), 5.34 (s, 1 H), 5.54 (s, 1 H), 6.92–6.94 
(m, 2 H), 7.23–7.31 (m, 3 H), 7.31–7.38 (m, 2 H), 7.54–7.63 (m, 1 H), 8.16–8.20 (m, 1 H) ppm. 
Minor conformer: 1H NMR (400 MHz, CDCl3, 25°C): δ = 0.51 (d, J = 5.9 Hz, 3 H), 0.63 (d, J = 
6.3 Hz, 3 H), 1.23–1.34 (m, 1 H), 2.94 (s, 3 H), 3.60–3.65 (m, 1 H), 5.54 (s, 1 H), 5.67 (s, 1 H), 
6.18 (s, 1 H), 6.91–8.24 (m, 9 H) ppm. 1H NMR (400 MHz, [D6]DMSO, 100°C): δ = 0.83 (d, J = 
6.9 Hz, 3 H), 0.89 (d, J = 6.7 Hz, 3 H), 1.55 (dqq, J = 6.7, 6.9, 7.3 Hz, 1 H), 2.77 (s, 3 H), 4.06 (d, 
J = 7.3 Hz, 1 H), 5.15 (s, 1 H), 5.27 (s, 1 H), 5.71 (s, 1 H), 7.11–7.12 (m, 2 H), 7.13–7.31 (m, 3 
H), 7.46 (dd, J = 1.3, 7.5 Hz, 1 H), 7.68 (ddd, J = 1.3, 7.7, 8.2 Hz, 1 H), 7.76 (ddd, J = 1.1, 7.5, 
7.7 Hz, 1 H), 8.16 (dd, J = 1.1, 8.2 Hz, 1 H) ppm. 13C NMR (100 MHz, [D6]DMSO, 100°C): δ = 
20.1 (q), 20.9 (q), 27.8 (d), 32.4 (q), 63.5 (d), 78.9 (d), 120.6 (s), 122.6 (t), 125.7 (d), 128.7 (d), 
128.9 (d), 129.1 (d), 129.8 (d), 131.6 (d), 132.3 (s), 135.8 (d), 138.1 (s), 144.9 (s), 145.0 (s), 169.7 
(s) ppm. MS: m/z = 393 [M]+. C22H23N3O4 (393.44): calcd. C 67.16, H 5.89, N 10.68; found C 
67.34, H 5.67, N 10.75. 
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      (2R,5S)-1-(5-Chloro-2-nitrobenzoyl)-5-isopropyl-3-methyl-2-(1-phenylvinyl) 
             imidazolidin-4-one (51ba) 
Yield 34% (as a mixture of two conformers in a ratio of 5:1); white crystals; m.p. 145°C (iPr2O). 
[α]D 25 = +55.7 (c = 13.0, CHCl3). IR (Nujol): ν˜ = 1644, 1710 cm–1. Major conformer: 1H NMR 
(400 MHz, CDCl3, 25°C): δ = 0.88 (d, J = 5.5 Hz, 3 H), 1.09 (d, J = 6.6 Hz, 3 H), 1.58 (dqq, J = 
5.5, 6.6, 8.9 Hz, 1 H), 2.85 (s, 3 H), 4.36 (d, J = 8.9 Hz, 1 H), 4.91 (s, 1 H), 5.26 (s, 1 H), 5.34 (s, 
1 H), 6.95–8.07 (m, 8 H) ppm. 13C NMR (100 MHz, CDCl3, 25°C): δ = 19.4 (q), 19.7 (q), 27.2 (d), 
32.2 (q), 63.3 (d), 78.6 (d), 120.0 (s), 121.3 (t), 125.9 (d), 127.2 (d), 128.3 (d), 128.6 (d), 128.8 (d), 
130.4 (d), 133.4 (s), 137.1 (s), 141.1 (s), 142.8 (s), 144.7 (s), 169.8 (s) ppm. Minor conformer: 1H 
NMR (400 MHz, CDCl3, 25°C): δ = 0.55 (d, J = 5.6 Hz, 3 H), 0.67 (d, J = 5.9 Hz, 3 H), 1.20–1.26 
(m, 1 H), 2.93 (s, 3 H), 3.57–3.63 (m, 1 H), 5.52 (s, 1 H), 5.62 (s, 1 H), 6.15 (s, 1 H), 6.95–8.07 
(m, 8 H) ppm. 13C NMR (100 MHz, CDCl3, 25°C): δ = 16.8 (q), 20.4 (q), 28.0 (d), 31.9 (q), 64.9 
(d), 77.4 (d), 120.0 (s), 121.3 (t), 126.3 (d), 127.8 (d), 128.1 (d), 128.6 (d), 129.5 (d), 130.6 (d), 
133.4 (s), 137.1 (s), 141.1 (s), 142.8 (s), 144.7 (s), 169.8 (s) ppm. MS: m/z = 427 [M]+. 
C22H22ClN3O4 (427.88): calcd. C 61.75, H 5.18, N 9.82; found C 61.89, H 5.03, N 10.02. 
 
      (2R,5S)-1-(5-Fluoro-2-nitrobenzoyl)-5-isopropyl-3-methyl-2-(1-phenylvinyl) 
             imidazolidin-4-one (51bb) 
Yield 49% (as a mixture of two conformers, in a ratio of 4:1); yellow oil. [α]D 25 = +0.24 (c = 
28.7, CHCl3). IR (Nujol): ν˜ = 1640, 1698 cm–1. Major conformer: 1H NMR (400 MHz, CDCl3, 
25°C): δ = 0.88 (d, J = 5.9 Hz, 3 H), 1.07 (d, J = 6.6 Hz, 3 H), 1.55 (dqq, J = 5.9, 6.6, 9.0 Hz, 1 
H), 2.82 (s, 3 H), 4.33 (d, J = 9.0 Hz, 1 H), 4.94 (s, 1 H), 5.24 (s, 1 H), 5.35 (s, 1 H), 6.91–8.15 
(m, 8 H) ppm. 13C NMR (100 MHz, CDCl3, 25°C): δ = 19.3 (q), 19.8 (q), 27.2 (d), 32.2 (q), 63.4 
(d), 78.4 (d), 116.6 (dd, 2JC-F = 27.4 Hz), 117.4 (dd, 2JC-F = 23.1 Hz), 120.9 (t), 127.2 (d), 
127.6 (dd, 3JC-F = 9.4 Hz), 128.3 (d), 128.6 (d), 134.4 (d, 3JC-F = 8.3 Hz), 137.3 (s), 140.7 (s), 
144.8 (s), 165.1 (d, 1JC-F = 259.7 Hz), 166.4 (s), 169.8 (s) ppm. Minor conformer: 1H NMR (400 
MHz, CDCl3, 25°C): δ = 0.49 (d, J = 6.2 Hz, 3 H), 0.64 (d, J = 6.6 Hz, 3 H), 1.32–1.42 (m, 1 H), 
2.89 (s, 3 H), 3.54–3.61 (m, 1 H), 5.48 (s, 1 H), 5.60 (s, 1 H), 6.12 (s, 1 H), 6.70–8.29 (m, 8 H) 
ppm. 13C NMR (100 MHz, CDCl3, 25°C): δ = 16.6 (q), 20.4 (q), 28.0 (d), 31.8 (q), 64.8 (d), 77.3 
(d), 116.4 (dd, 2JC-F = 27.2 Hz), 117.6 (dd, 2JC-F = 23.5 Hz), 120.0 (t), 127.2 (d), 127.8 (dd, 
3JC-F = 9.0 Hz), 128.0 (d), 128.6 (d), 134.2 (d, 3JC-F = 8.2 Hz), 138.0 (s), 139.9 (s), 144.2 (s), 
165.4 (d, 1JC-F = 259.4 Hz), 166.8 (s), 170.1 (s) ppm. MS: m/z = 411 [M]+. C22H22FN3O4 
(411.43): calcd. C 64.22, H 5.39, N 10.21; found C 64.44, H 5.12, N 10.32. 
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 (2R,5S)-5-Benzyl-3-methyl-1-(2-nitrobenzoyl)-2-(1-phenylvinyl)imidazolidin- 
             4-one (51c) 
Yield 50% (as a mixture of two conformers, in a ratio of 1:1); yellow oil. [α]D 25 = +4.3 (c = 0.1, 
CHCl3). IR (Nujol): ν˜ = 1658, 1706 cm–1. 1H NMR (400 MHz, CDCl3, 25°C): δ = 2.46–2.52 (m, 
2 H), 2.81 (s, 3 H), 3.10 (s, 3 H), 3.15–3.22 (m, 2 H), 3.93–4.12 (m, 1 H), 4.17 (s, 1 H), 4.85–4.88 
(m, 1 H), 5.17 (s, 1 H), 5.43 (s, 1 H), 5.59 (s, 1 H), 5.71 (s, 1 H), 6.19 (s, 1 H), 6.48–7.92 (m, 28 
H) ppm. 13C NMR (100 MHz, CDCl3, 25°C): δ = 26.9 (q), 27.6 (q), 36.8 (t), 39.0 (t), 60.5 (d), 61.4 
(d), 76.7 (d), 78.7 (d), 121.4 (t), 121.8 (t), 125.1 (d), 125.7 (d), 126.2 (d), 127.0 (d), 127.5 (d), 
128.0 (d), 128.2 (d), 128.3 (d), 128.4 (d), 128.5 (d, overlapped), 128.6 (d), 129.3 (d), 129.4 (d), 
129.8 (d), 130.0 (d), 130.3 (d), 130.4 (d), 130.8 (d), 132.4 (d), 133.0 (d), 136.1 (s), 136.9 (s), 137.2 
(s), 137.4 (s), 141.1 (s), 141.4 (s), 142.5 (s), 142.7 (s), 143.9 (s), 144.0 (s), 168.6 (s), 168.8 (s), 
169.2 (s), 169.6 (s) ppm. MS: m/z = 441 [M]+. C26H23N3O4 (441.48): calcd. C 70.73, H 5.25, N 
9.52; found C 70.50, H 5.51, N 9.43. 
 
      (2R,5S)-5-Benzyl-1-(5-chloro-2-nitrobenzoyl)-3-methyl-2-(1-phenylvinyl) 
             imidazolidin-4-one (51ca) 
Yield 62% (as a mixture of two conformers in a ratio of 1:1); pale-yellow crystals; m.p. 75°C 
(iPr2O). [α]D 25 = +4.4 (c = 11.9, CHCl3). IR (Nujol): ν˜ = 1636, 1688 cm–1. 1H NMR (400 MHz, 
CDCl3, 25°C): δ = 2.79 (s, 3 H), 2.84–2.95 (m, 2 H), 3.07 (s, 3 H), 3.12–3.20 (m, 2 H), 3.93–4.15 
(m, 1 H), 4.21 (s, 1 H), 4.80–4.86 (m, 1 H), 5.16 (s, 1 H), 5.44 (s, 1 H), 5.57 (s, 1 H), 5.68 (s, 1 H), 
6.18 (s, 1 H), 6.47–6.51 (m, 2 H), 6.75–7.48 (m, 22 H), 7.84–7.96 (m, 2 H) ppm. 13C NMR (100 
MHz, CDCl3, 25°C): δ = 26.9 (q), 27.6 (q), 36.8 (t), 39.0 (t), 60.5 (d), 61.4 (d), 76.9 (d), 78.6 (d), 
121.5 (t), 121.7 (t), 125.7 (d), 126.1 (d), 126.3 (d), 126.9 (d), 127.2 (d), 128.2 (d), 128.3 (d), 128.4 
(d), 128.5 (d), 128.6 (d, overlapped), 128.7 (d), 129.4 (d), 129.7 (d), 129.8 (d), 130.0 (d), 130.3 (d), 
130.4 (d), 132.4 (s), 133.0 (s), 136.1 (s), 136.9 (s), 137.2 (s), 137.7 (s), 141.0 (s), 141.2 (s), 142.4 
(s), 142.5 (s), 144.0 (s), 168.6 (s), 168.7 (s), 169.1 (s), 169.4 (s) ppm. MS: m/z = 475 [M]+. 
C26H22ClN3O4 (475.92): calcd. C 65.62, H 4.66, N 8.83; found C 65.43, H 4.81, N 8.96. 
 
      (2R,5S)-5-Benzyl-1-(5-fluoro-2-nitrobenzoyl)-3-methyl-2-(1-phenylvinyl)- 
             imidazolidin-4-one (51cb) 
Yield 65% (as a mixture of two conformers in a ratio of 1:1); white crystals; m.p. 88°C (iPr2O). 
[α]D 25 = –4.0 (c = 19.1, CHCl3). IR (Nujol): ν˜ = 1660, 1700 cm–1. 1H NMR (400 MHz, CDCl3, 
25°C): δ = 2.48–2.56 (m, 2 H), 2.79 (s, 3 H), 3.08 (s, 3 H), 3.01–3.20 (m, 2 H), 3.92–4.13 (m, 1 
H), 4.21 (s, 1 H), 4.82–4.89 (m, 1 H), 5.15 (s, 1 H), 5.44 (s, 1 H), 5.58 (s, 1 H), 5.69 (s, 1 H), 6.21 
(s, 1 H), 6.25–6.42 (m, 1 H), 6.48–6.51 (m, 3 H), 6.75–7.08 (m, 7 H), 7.25–7.48 (m, 12 H), 7.98–
8.05 (m, 3 H) ppm. 13C NMR (100 MHz, CDCl3, 25 °C): δ = 26.9 (q), 27.6 (q), 36.8 (t), 39.1 (t), 
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60.6 (d), 61.5 (d), 76.7 (d), 78.6 (d), 116.0 (dd, 2JC-F = 21.8 Hz), 116.2 (dd, 2JC-F = 22.0 Hz), 
117.1 (dd, 2JC-F = 21.6 Hz), 117.4 (dd, 2JC-F = 21.9 Hz), 121.3 (t), 121.7 (t), 126.2 (d), 126.8 
(dd, 3JC-F = 11.6 Hz), 127.4 (dd, 3JC-F = 11.0 Hz), 128.4 (d), 128.6 (d, overlapped), 130.0 (d), 
133.5 (d, 3JC-F = 5.6 Hz), 134.3 (d, 3JC-F = 6.2 Hz), 136.3 (s), 136.6 (s), 136.7 (s), 137.0 (s), 
137.4 (s), 137.7 (s), 144.0 (s), 144.2 (s), 165.1 (d, 1JC-F = 231.6 Hz), 166.4 (s), 167.6 (d, 1JC-F = 
259.3 Hz), 168.7 (s), 168.8 (s), 169.1 (s) ppm. MS: m/z = 459 [M]+. C26H22FN3O4 (459.47): calcd. 
C 67.97, H 4.83, N 9.15; found C 67.84, H 4.99, N 9.26. 
 
General Procedure for the Synthesis of Compounds 52 
A solution of 51 (1.04 mmol) in EtOH (10 mL) and 20% aq. AcOH (2.5 mL) was treated with Fe 
powder (0.464 g, 8.32 mmol) and heated at reflux for 5 h under vigorous stirring. The mixture 
was diluted with AcOEt (50 mL) and filtered through a pad of Celite. The filtrate was washed 
with aq. NaHCO3 (50 mL) and water (2x25 mL) and then the organic layer was dried with 
Na2SO4. The solvent was evaporated under reduced pressure and the products purified by 
column chromatography with light petroleum ether/AcOEt (1:1) as eluent. 
 
      (2R,5S)-1-(2-Aminobenzoyl)-3,5-dimethyl-2-(1-phenylvinyl)-imidazolidin- 
             4-one (52a) 
Yield 96%; yellow oil. [α]D 25 = +25.3 (c = 0.22, CHCl3). IR (Nujol): ν˜ = 1648, 1698, 3488 cm–1. 
1H NMR (400 MHz, CDCl3, 25°C): δ = 0.66 (d, J = 6.9 Hz, 3 H), 2.96 (s, 3 H), 4.13 (br. s, 2 H), 
4.30 (q, J = 6.9 Hz, 1 H), 5.36 (s, 2 H), 5.87 (s, 1 H), 6.70–6.75 (m, 2 H), 7.00–7.35 (m, 7 H) 
ppm. 13C NMR (100 MHz, CDCl3, 25°C): δ = 17.3 (q), 27.5 (q), 55.9 (d), 79.5 (d), 117.1 (d), 118.2 
(d), 119.2 (s), 121.3 (s), 121.8 (t), 127.2 (d), 127.6 (d), 128.8 (d), 128.9 (d), 131.4 (d), 137.8 (s), 
144.7 (s), 144.9 (s), 171.1 (s) ppm. MS: m/z = 335 [M]+. C20H21N3O2 (335.40): calcd. C 71.62, H 
6.31, N 12.53; found C 71.45, H 6.52, N 12.33.  
 
      (2R,5S)-1-(2-Amino-5-chlorobenzoyl)-3,5-dimethyl-2-(1-phenylvinyl)- 
             imidazolidin-4-one (52aa) 
Yield 96%; yellow crystals; m.p. 106°C (iPr2O). [α]D 25 = +21.4 (c = 24.1, CHCl3). IR (Nujol): ν˜ 
= 1636, 1694, 3448 cm–1. 1H NMR (400 MHz, CDCl3, 25°C): δ = 0.55 (d, J = 6.6 Hz, 3 H), 2.80 
(s, 3 H), 4.15 (q, J = 6.6 Hz, 1 H), 4.26 (br. s, 2 H), 5.16 (s, 1 H), 5.20 (s, 1 H), 5.68 (s, 1 H), 
6.51–6.54 (m, 1 H), 6.90–6.97 (m, 4 H), 7.13–7.21 (m, 3 H) ppm. 13C NMR (100 MHz, CDCl3, 
25°C): δ = 16.6 (q), 26.9 (q), 55.2 (d), 79.0 (d), 117.4 (d), 121.4 (t), 121.5 (s), 121.6 (s), 126.5 (d), 
128.0 (d), 128.3 (d), 128.4 (d), 130.6 (d), 137.1 (s), 143.1 (s), 144.2 (s), 170.0 (s), 170.3 (s) ppm. 
MS: m/z = 369 [M]+. C20H20ClN3O2 (369.84): calcd. C 64.95, H 5.45, N 11.36; found C 64.87, H 
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5.61, N 11.27. Eur. J. Org. Chem. 2010, 1694–1703 © 2010 Wiley-VCH Verlag GmbH & Co. 
KGaA, Weinheim www.eurjoc.org 1699. 
 
      (2R,5S)-1-(2-Amino-5-fluorobenzoyl)-3,5-dimethyl-2-(1-phenylvinyl)- 
             imidazolidin-4-one (52ab) 
Yield 87%; colorless oil. [α]D 25 = +9.9 (c = 2.43, CHCl3). IR (Nujol): ν˜ = 1654, 1702, 3450 cm–
1. 1H NMR (400 MHz, CDCl3, 25°C): δ = 0.67 (d, J = 7.0 Hz, 3 H), 2.96 (s, 3 H), 3.87 (br. s, 2 H), 
4.12 (q, J = 7.0 Hz, 1 H), 5.37 (s, 2 H), 5.82 (s, 1 H), 6.61–7.35 (m, 8 H) ppm. 13C NMR (100 
MHz, CDCl3, 25°C): δ = 17.2 (q), 27.4 (q), 55.7 (d), 79.4 (d), 113.8 (dd, 2JC-F = 23.7 Hz), 118.1 
(dd, 2JC-F = 22.1 Hz), 118.3 (dd, 3JC-F = 7.2 Hz), 121.9 (t), 122.0 (d, 3JC-F = 6.6 Hz), 128.6 
(d), 128.8 (d), 129.0 (d), 137.5 (s), 140.7 (s), 144.8 (s), 155.5 (d, 1JC-F = 238.3 Hz), 168.4 (s), 
170.8 (s) ppm. MS: m/z = 353 [M]+. C20H20FN3O2 (353.39): calcd. C 67.97, H 5.70, N 11.89; 
found C 67.86, H 5.82, N 11.74. 
 
      (2R,5S)-1-(2-Aminobenzoyl)-5-isopropyl-3-methyl-2-(1-phenylvinyl)- 
             imidazolidin-4-one (52b) 
Yield 95%; colorless oil. [α]D 25 = +56.1 (c = 0.38, CHCl3). IR (Nujol): ν˜ = 1640, 1690, 3492 
cm–1.  1H NMR (400 MHz, CDCl3, 25°C): δ = 0.75 (d, J = 6.8 Hz, 3 H), 0.97 (d, J = 6.5 Hz, 3 H), 
1.26–1.29 (qqd, J = 6.5, 6.8, 9.1 Hz, 1 H), 2.81 (s, 3 H), 4.15 (br. s, 2 H), 4.35 (d, J = 9.1 Hz, 1 
H), 5.24 (s, 1 H), 5.36 (s, 1 H), 5.64 (s, 1 H), 6.70–6.75 (m, 2 H), 7.13–7.34 (m, 7 H) ppm. 13C 
NMR (100 MHz, CDCl3, 25°C): δ = 19.3 (q), 20.6 (q), 28.0 (d), 32.6 (q), 63.6 (d), 79.5 (d), 117.1 
(d), 117.7 (d), 120.7 (s), 121.2 (t), 128.2 (d), 128.4 (d), 128.7 (d), 128.8 (d), 131.7 (d), 138.3 (s), 
145.4 (s), 145.8 (s), 170.6 (s), 172.5 (s) ppm. MS: m/z = 363 [M]+. C22H25N3O2 (363.45): calcd. C 
72.70, H 6.93, N 11.56; found C 72.58, H 7.02, N 11.78. 
 
       (2R,5S)-1-(2-Amino-5-chlorobenzoyl)-5-isopropyl-3-methyl-2-(1-phenylvinyl)- 
             imidazolidin-4-one (52ba) 
Yield 84%; colorless oil. [α]D 25 = +63.7 (c = 12.0, CHCl3). IR (Nujol): ν˜ = 1654, 1706, 3466 
cm–1. 1H NMR (400 MHz, CDCl3, 25°C): δ = 0.67 (d, J = 6.6 Hz, 3 H), 0.96 (d, J = 6.3 Hz, 3 H), 
1.23–1.25 (m, 1 H), 2.78 (s, 3 H), 4.30 (br. s, 2 H), 4.32–4.36 (m, 1 H), 5.15 (s, 1 H), 5.36 (s, 1 
H), 5.51 (s, 1 H), 6.63–6.65 (m, 1 H), 7.11–7.31 (m, 7 H) ppm. 13C NMR (100 MHz, CDCl3, 
25°C): δ = 19.0 (q), 20.0 (q), 27.5 (d), 32.1 (q), 62.9 (d), 79.5 (d), 117.8 (d), 120.9 (s), 121.5 (t), 
121.9 (s), 127.9 (d), 128.0 (d), 128.4 (d), 128.5 (d), 131.0 (d), 137.4 (s), 143.7 (s), 145.0 (s), 170.0 
(s), 171.0 (s) ppm. MS: m/z = 397 [M]+. C22H24ClN3O2 (397.90): calcd. C 66.41, H 6.08, N 10.56; 
found C 66.53, H 6.01, N 10.44. 
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 (2R,5S)-1-(2-Amino-5-fluorobenzoyl)-5-isopropyl-3-methyl-2-(1-phenylvinyl)- 
             imidazolidin-4-one (52bb) 
Yield 93%; white crystals; m.p. 44°C (iPr2O). [α]D 25 = +26.7 (c = 21.8, CHCl3). IR (Nujol): ν˜ = 
1640, 1696, 3438 cm–1. 1H NMR (400 MHz, CDCl3, 25°C): δ = 0.73 (d, J = 6.8 Hz, 3 H), 0.97 (d, 
J = 6.5 Hz, 3 H), 1.32 (qqd, J = 6.5, 6.8, 9.0 Hz, 1 H), 2.83 (s, 3 H), 3.47 (br. s, 2 H), 4.29 (d, J = 
9.0 Hz, 1 H), 5.20 (s, 1 H), 5.36 (s, 1 H), 5.60 (s, 1 H), 6.65–7.35 (m, 8 H) ppm. 13C NMR (100 
MHz, CDCl3, 25°C): δ = 18.8 (q), 20.1 (q), 27.5 (d), 32.1 (q), 63.1 (d), 78.9 (d), 114.3 (dd, 2JC-F = 
23.8 Hz), 117.7 (dd, 3JC-F = 8.1 Hz), 117.8 (dd, 2JC-F = 20.2 Hz), 120.9 (t), 121.2 (d, 3JC-F = 
6.1 Hz), 127.9 (d), 128.3 (d), 128.4 (d), 137.6 (s), 140.8 (s), 145.2 (s), 154.8 (d, 1JC-F = 236.3 
Hz), 169.9 (s), 170.6 (s) ppm. MS: m/z = 381 [M]+. C22H24FN3O2 (381.44): calcd. C 69.27, H 6.34, 
N 11.02; found C 69.41, H 6.12, N 11.29.  
 
      (2R,5S)-1-(2-Aminobenzoyl)-5-benzyl-3-methyl-2-(1-phenylvinyl)- 
            imidazolidin-4-one (52c) 
Yield 97%; yellow crystals; m.p. 130°C (iPr2O). [α]D 25 = +130.0 (c = 0.28, CHCl3). IR (Nujol): 
ν˜ = 1642, 1696, 3472 cm–1. 1H NMR (400 MHz, CDCl3, 25 °C): δ = 1.87–1.94 (m, 1 H), 2.37–
2.43 (m, 1 H), 2.93 (s, 3 H), 4.01 (br. s, 2 H), 4.50–4.54 (m, 1 H), 5.19 (s, 1 H), 5.46 (s, 1 H), 5.80 
(s, 1 H), 6.71–7.40 (m, 14 H) ppm. 13C NMR (100 MHz, CDCl3, 25°C): δ = 27.5 (q), 38.7 (t), 60.5 
(d), 79.0 (d), 117.2 (d), 118.3 (d), 121.1 (s), 121.7 (t), 126.8 (d), 127.4 (d), 128.5 (d), 128.8 (d, 
overlapped), 128.9 (d), 129.8 (d), 131.5 (d), 137.4 (s), 138.0 (s), 144.8 (s), 145.0 (s), 169.9 (s), 
170.2 (s) ppm. MS: m/z = 411 [M]+. C26H25N3O2 (411.50): calcd. C 75.89, H 6.12, N 10.21; found 
C 76.02, H 5.97, N 10.40. 
 
      (2R,5S)-1-(2-Amino-5-chlorobenzoyl)-5-benzyl-3-methyl-2-(1-phenylvinyl)- 
             imidazolidin-4-one (52ca) 
Yield 79%; yellow oil. [α]D 25 = +13.7 (c = 8.47, CHCl3). IR (Nujol): ν˜ = 1650, 1696, 3480 cm–1. 
1H NMR (400 MHz, CDCl3, 25°C): δ = 2.03–2.36 (m, 2 H), 2.93 (s, 3 H), 4.15 (br. s, 2 H), 4.56–
4.60 (m, 1 H), 5.12 (s, 1 H), 5.36 (s, 1 H), 5.70 (s, 1 H), 6.58–7.41 (m, 13 H) ppm. 13C NMR (100 
MHz, CDCl3, 25°C): δ = 27.1 (q), 38.2 (t), 60.0 (d), 78.9 (d), 113.4 (d), 118.0 (d), 121.4 (s), 121.7 
(t), 122.4 (s), 126.6 (d), 127.1 (d), 128.2 (d), 128.4 (d), 128.6 (d), 129.3 (d), 129.4 (d), 130.9 (d), 
131.3 (d), 136.9 (s), 137.3 (s), 143.2 (s), 144.4 (s), 168.7 (s), 169.3 (s) ppm. MS: m/z = 445 [M]+. 
C26H24ClN3O2 (445.94): calcd. C 70.03, H 5.42, N 9.42; found C 70.18, H 5.31, N 9.38.  
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(2R,5S)-1-(2-Amino-5-fluorobenzoyl)-5-benzyl-3-methyl-2-(1-phenylvinyl)- 
             imidazolidin-4-one (52cb) 
Yield 60%; white crystals; m.p. 142°C (iPr2O). [α]D 25 = +4.7 (c = 5.07, CHCl3). IR (Nujol): ν˜ = 
1662, 1708, 3490 cm–1. 1H NMR (400 MHz, CDCl3, 25°C): δ = 2.03–2.36 (m, 2 H), 2.93 (s, 3 H), 
4.15 (br. s, 2 H), 4.56–4.60 (m, 1 H), 5.12 (s, 1 H), 5.36 (s, 1 H), 5.70 (s, 1 H), 6.58–7.41 (m, 13 
H) ppm. 13C NMR (100 MHz, CDCl3, 25°C): δ = 27.1 (q), 38.2 (t), 60.0 (d), 78.6 (d), 113.7 (dd, 
2JC-F = 23.7 Hz), 117.9 (dd, 2JC-F = 22.6 Hz), 118.1 (dd, 3JC-F = 7.4 Hz), 121.5 (t), 121.2 (d, 
3JC-F = 6.1 Hz), 126.6 (d), 128.2 (d), 128.4 (d), 128.6 (d, overlapped), 129.4 (d), 137.6 (s), 137.4 
(s), 140.4 (s), 144.4 (s), 155.2 (d, 1JC-F = 236.8 Hz), 168.6 (s), 169.4 (s) ppm. MS: m/z = 429 
[M]+. C26H24FN3O2 (429.49): calcd. C 72.71, H 5.63, N 9.78; found C 72.60, H 5.81, N 9.61. 
 
General Procedure for the Synthesis of Compounds 53 
NaNO2 (0.156 g, 2.26 mmol) was added portion wise to a solution of 52 (1.13 mmol) in MeOH 
(2 mL) and 6 N HCl (0.65 mL) cooled to 0°C. After 30 min AcONa was added until pH 5 and 
then a solution of ethyl 2-chloroacetoacetate (1.13 mmol, 0.122 mL) in MeOH (1 mL) was 
added dropwise under vigorous stirring at room temperature. After 24 h the solvent was 
evaporated under reduced pressure and the residue extracted with Et2O (2x15 mL). The 
organic layer was washed with aq. NaHCO3 (15 mL) and water (30 mL) and then dried with 
Na2SO4. The solvent was evaporated under reduced pressure and the products purified by 
silica gel column chromatography with light petroleum ether/AcOEt (1:1) as eluent. 
 
      Ethyl (2R,5S)-2-Chloro-2-(2-{2-[3,5-dimethyl-4-oxo-2-(1-phenylvinyl)- 
             imidazolidin-1-ylcarbonyl]phenyl}hydrazono)acetate (53a) 
Yield 57%; pale-yellow crystals; m.p. 65°C (iPr2O). [α]D 25 = +2.1 (c = 0.15, CHCl3). IR (Nujol): 
ν˜ = 1650, 1703, 1716, 3338 cm–1. 1H NMR (400 MHz, CDCl3, 25°C): δ = 0.62 (d, J = 6.6 Hz, 3 
H), 1.42 (t, J = 7.1 Hz, 3 H), 2.98 (s, 3 H), 4.35 (q, J = 6.6 Hz, 1 H), 4.41 (q, J = 7.1 Hz, 2 H), 
5.38 (s, 1 H), 5.40 (s, 1 H), 5.91 (s, 1 H), 7.00–7.61 (m, 9 H), 9.40 (s, 1 H) ppm. 13C NMR (100 
MHz, CDCl3, 25°C): δ = 14.6 (q), 17.1 (q), 27.5 (q), 56.2 (d), 63.3 (t), 79.9 (d), 116.7 (d), 118.5 (s), 
121.0 (s), 122.1 (t), 122.4 (d), 127.3 (d), 128.8 (d), 128.9 (d), 132.1 (d), 132.2 (d), 137.4 (s), 140.3 
(s), 144.7 (s), 159.2 (s), 168.5 (s), 170.7 (s) ppm. MS: m/z = 468 [M]+. C24H25ClN4O4 (468.93): 
calcd. C 61.47, H 5.37, N 11.95; found C 61.34, H 5.48, N 11.77. 
 
      Ethyl (2R,5S)-2-Chloro-2-(2-{4-chloro-2-[3,5-dimethyl-4-oxo-2-(1- 
             phenylvinyl)-imidazolidin-1-ylcarbonyl]phenyl}hydrazono)acetate (53aa) 
Yield 62%; pale-yellow crystals; m.p. 174°C (iPr2O). [α]D 25 = +2.4 (c = 17.8, CHCl3). IR 
(Nujol): ν˜ = 1646, 1694, 1728, 3392 cm–1. 1H NMR (400 MHz, CDCl3, 25°C): δ = 0.66 (d, J = 
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6.5 Hz, 3 H), 1.37 (t, J = 6.9 Hz, 3 H), 2.94 (s, 3 H), 4.31–4.37 (m, 3 H), 5.37 (s, 2 H), 5.83 (s, 1 
H), 7.04–7.47 (m, 8 H), 9.33 (s, 1 1700 ppm. 13C NMR (100 MHz, CDCl3, 25°C): δ = 14.2 (q), 
16.7 (q), 27.0 (q), 55.6 (d), 63.0 (t), 79.6 (d), 117.8 (d), 118.6 (s), 121.7 (s), 121.8 (s), 121.9 (t), 
127.0 (d), 128.3 (d), 128.5 (d), 128.6 (d), 131.4 (d), 136.8 (s), 138.4 (s), 144.1 (s), 159.1 (s), 167.0 
(s), 170.1 (s) ppm. MS: m/z = 502 [M]+. C24H24Cl2N4O4 (503.38): calcd. C 
57.26, H 4.81, N 11.13; found C 57.40, H 4.62, N 11.21. 
 
     Ethyl (2R,5S)-2-Chloro-2-(2-{2-[3,5-dimethyl-4-oxo-2-(1-phenylvinyl)- 
             imidazolidin-1-ylcarbonyl]-4-fluorophenyl}hydrazono)acetate (53ab) 
Yield 49%; yellow crystals; m.p. 125°C (iPr2O). [α]D 25 = –0.35 (c = 10.3, CHCl3). IR (Nujol): ν˜ 
= 1642, 1708, 1732, 3412 cm–1. 1H NMR (400 MHz, CDCl3, 25°C): δ = 0.64 (d, J = 6.3 Hz, 3 H), 
1.39 (t, J = 7.1 Hz, 3 H), 2.96 (s, 3 H), 4.30 (q, J = 6.3 Hz, 1 H), 4.37 (q, J = 7.1 Hz, 2 H), 5.38 
(s, 2 H), 5.86 (s, 1 H), 6.95–7.51 (m, 8 H), 9.22 (s, 1 H) ppm. 13C NMR (100 MHz, CDCl3, 25°C): 
δ = 14.2 (q), 16.7 (q), 27.0 (q), 55.7 (d), 62.9 (t), 79.4 (d), 113.8 (dd, 2JC-F = 24.3 Hz), 118.0 (s), 
118.2 (dd, 3JC-F = 7.5 Hz), 118.5 (dd, 2JC-F = 22.4 Hz), 121.8 (t), 128.3 (d), 128.5 (d), 
128.6 (d), 136.1 (s), 136.8 (s), 140.6 (s), 144.1 (s), 157.5 (d, 1JC-F = 242.8 Hz), 159.2 (s), 166.8 
(s), 170.1 (s) ppm. MS: m/z = 486 [M]+. C24H24ClFN4O4 (486.92): calcd. C 59.20, H 4.97, N 
11.51; found C 59.08, H 5.12, N 11.31. 
 
      Ethyl (2R,5S)-2-Chloro-2-(2-{2-[5-isopropyl-3-methyl-4-oxo-2-(1-           
             phenylvinyl)-imidazolidin-1-ylcarbonyl]phenyl}hydrazono)acetate (53b) 
Yield 51%; cream crystals; m.p.69°C (iPr2O). [α]D 25 = +45.6 (c = 0.4, CHCl3). IR (Nujol): ν˜ = 
1656, 1688, 1724, 3436 cm–1. 1H NMR (400 MHz, CDCl3, 25°C): δ = 0.72 (d, J = 6.8 Hz, 3 H), 
0.98 (d, J = 6.5 Hz, 3 H), 1.17–1.21 (m, 1 H), 1.43 (t, J = 7.1 Hz, 3 H), 2.83 (s, 3 H), 4.39–4.45 
(m, 3 H), 5.32 (s, 1 H), 5.42 (s, 1 H), 5.68 (s, 1 H), 7.01 (dd, J = 7.4, 7.5 Hz, 1 H), 7.10–7.13 (m, 
2 H), 7.27–7.36 (m, 3 H), 7.40 (d, J = 7.5 Hz, 1 H), 7.45 (dd, J = 7.4, 8.2 Hz, 1 H), 7.64 (d, J = 
8.2 Hz, 1 H), 9.51 (s, 1 H) ppm. 13C NMR (100 MHz, CDCl3, 25°C): δ = 14.6 (q), 19.3 (q), 20.5 
(q), 28.0 (d), 32.6 (q), 63.3 (t), 63.8 (d), 79.7 (d), 116.7 (d), 118.9 (s), 120.6 (s), 121.4 (t), 122.0 
(d), 128.2 (d), 128.3 (d), 128.9 (d), 129.0 (d), 132.4 (d), 138.1 (s), 140.8 (s), 145.8 (s), 159.9 (s), 
170.3 (s), 171.2 (s) ppm. MS: m/z = 496 [M]+. C26H29ClN4O4 (496.99): calcd. C 62.83, H 5.88, N 
11.27; found C 62.71, H 5.96, N 11.10.  
 
      Ethyl (2R,5S)-2-Chloro-2-(2-{4-chloro-2-[5-isopropyl-3-methyl-4-oxo-2-(1-  
             phenylvinyl)imidazolidin-1-ylcarbonyl]phenyl}hydrazono)-acetate (53ba) 
Yield 82%; pale-yellow oil. [α]D 25 = –0.81 (c = 6.20, CHCl3). IR (Nujol): ν˜ = 1634, 1686, 1716, 
3424 cm–1. 1H NMR (400 MHz, CDCl3, 25°C): δ = 0.62 (d, J = 6.6 Hz, 3 H), 0.91 (d, J = 6.4 Hz, 
77 
 
3 H), 1.00–1.09 (m, 1 H), 1.33 (t, J = 7.1 Hz, 3 H), 2.77 (s, 3 H), 4.27–4.35 (m, 3 H), 5.18 (s, 1 
H), 5.36 (s, 1 H), 5.53 (s, 1 H), 7.05–7.48 (m, 8 H), 9.49 (s, 1 H) ppm. 13C NMR (100 MHz, 
CDCl3, 25°C): δ = 14.1 (q), 18.9 (q), 19.9 (q), 27.4 (d), 32.0 (q), 62.9 (t), 63.0 (d), 79.6 (d), 117.7 
(d), 118.8 (s), 121.2 (s), 121.7 (t), 126.7 (s), 127.8 (d), 127.9 (d), 128.3 (d), 128.5 (d), 131.6 (d), 
137.2 (s), 138.9 (s), 145.0 (s), 159.2 (s), 169.8 (s), 169.9 (s) ppm. MS: m/z = 530 [M]+. 
C26H28Cl2N4O4 (531.43): calcd. C 58.76, H 5.31, N 10.54; found C 58.54, H 5.44, N 10.43. 
 
    Ethyl (2R,5S)-2-Chloro-2-(2-{4-fluoro-2-[5-isopropyl-3-methyl-4-oxo-2-(1-  
             phenylvinyl)imidazolidin-1-ylcarbonyl]phenyl}hydrazono)-acetate (53bb) 
Yield 57%; colorless oil. [α]D 25 = +16.4 (c = 5.00, CHCl3). IR (Nujol): ν˜ = 1638, 1710, 1722, 
3384 cm–1. 1H NMR (400 MHz, CDCl3, 25°C): δ = 0.70 (d, J = 6.8 Hz, 3 H), 0.97 (d, J = 6.5 Hz, 
3 H), 1.18–1.23 (m, 1 H), 1.40 (t, J = 7.1 Hz, 3 H), 2.83 (s, 3 H), 4.33–4.41 (m, 3 H), 5.29 (s, 1 
H), 5.42 (s, 1 H), 5.64 (s, 1 H), 7.08–7.17 (m, 4 H), 7.27–7.33 (m, 3 H), 7.53–7.57 (m, 1 H), 9.30 
(s, 1 H) ppm. 13C NMR (100 MHz, CDCl3, 25°C): δ = 14.2 (q), 18.9 (q), 20.3 (q), 27.5 (d), 32.1 (q), 
62.9 (t), 63.3 (d), 79.2 (d), 114.7 (dd, 2JC-F = 24.4 Hz), 118.1 (dd, 3JC-F = 7.4 Hz), 118.5 (s), 
118.8 (dd, 2JC-F = 22.3 Hz), 121.3 (t), 127.8 (d), 128.6 (d), 128.9 (d), 136.6 (s), 137.3 (s), 140.0 
(s), 145.2 (s), 157.2 (d, 1JC-F = 242.7 Hz), 159.3 (s), 169.5 (s), 169.7 (s) ppm. MS: m/z = 514 
[M]+. C26H28ClFN4O4 (514.98): calcd. C 60.64, H 5.48, N 10.88; found C 60.88, H 5.23, N 10.65.  
 
      Ethyl (2R,5S)-2-(2-{2-[5-Benzyl-3-methyl-4-oxo-2-(1-phenylvinyl)-imidazolidin- 
             1-ylcarbonyl]phenyl}hydrazono)-2-chloroacetate (53c) 
Yield 44%; yellow oil. [α]D 25 = –33.8 (c = 0.21, CHCl3). IR (Nujol): ν˜ = 1646, 1692, 1720, 3404 
cm–1. 1H NMR (400 MHz, CDCl3, 25°C): δ = 1.42 (t, J = 7.1 Hz, 3 H), 2.01–2.05 (m, 1 H), 2.08–
2.13 (m, 1 H), 2.98 (s, 3 H), 4.41 (q, J = 7.1 Hz, 2 H), 4.60 (t, J = 4.7 Hz, 1 H), 5.23 (s, 1 H), 5.37 
(s, 1 H), 5.83 (s, 1 H), 6.75–7.56 (m, 14 H), 9.31 (s, 1 H) ppm. 13C NMR (100 MHz, CDCl3, 
25°C): δ = 14.6 (q), 27.5 (q), 38.7 (t), 60.9 (d), 63.3 (t), 79.4 (d), 116.8 (d), 118.5 (s), 120.9 (s), 
122.0 (t), 122.4 (d), 126.5 (d), 126.9 (d), 127.5 (d), 128.6 (d), 128.8 (d), 129.3 (d), 129.7 (d), 132.1 
(d), 136.8 (s), 137.8 (s), 140.3 (s), 144.8 (s), 159.8 (s), 168.9 (s), 169.6 (s) ppm. MS: m/z = 544 
[M]+. C30H29ClN4O4 (545.03): calcd. C 66.11, H 5.36, N 10.28; found C 65.98, H 5.54, N 10.12.  
 
      Ethyl (2R,5S)-2-(2-{2-[5-Benzyl-3-methyl-4-oxo-2-(1-phenylvinyl)- 
             imidazolidin-1-ylcarbonyl]-4-chlorophenyl}hydrazono)-2-chloroacetate (53ca) 
Yield 43%; yellow oil. [α]D 25 = +0.022 (c = 4.49, CHCl3). IR (Nujol): ν˜ = 1650, 1702, 1726, 
3456 cm–1. 1H NMR (400 MHz, CDCl3, 25°C): δ = 1.41 (t, J = 7.1 Hz, 3 H), 2.22–2.26 (m, 2 H), 
2.98 (s, 3 H), 4.40 (q, J = 7.1 Hz, 2 H), 4.65 (t, J = 6.4 Hz, 1 H), 5.19 (s, 1 H), 5.40 (s, 1 H), 5.79 
(s, 1 H), 6.77–6.80 (m, 2 H), 7.10–7.43 (m, 11 H), 9.24 (s, 1 H) ppm. 13C NMR (100 MHz, CDCl3, 
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25°C): δ = 14.2 (q), 27.1 (q), 38.3 (t), 60.3 (d), 63.0 (t), 79.3 (d), 117.8 (d), 118.7 (s), 121.3 (s), 
122.0 (t), 126.6 (d), 127.0 (s), 127.1 (d), 128.3 (d), 128.7 (d), 128.8 (d, overlapped), 129.1 (d), 
130.2 (d), 131.5 (d), 136.3 (s), 137.3 (s), 138.6 (s), 144.2 (s), 159.2 (s), 167.4 (s), 169.0 (s) ppm. 
MS: m/z = 578 [M]+. C30H28Cl2N4O4 (579.47): calcd. C 62.18, H 4.87, N 9.67; found C 61.95, H 
5.04, N 9.87. 
 
       Ethyl (2R,5S)-2-(2-{2-[5-Benzyl-3-methyl-4-oxo-2-(1-phenylvinyl)- 
             imidazolidin-1-ylcarbonyl]-4-fluorophenyl}hydrazono)-2-chloroacetate (53cb) 
Yield 47%; yellow crystals; m.p. 105°C (iPr2O). [α]D 25 = –0.13 (c = 4.43, CHCl3). IR (Nujol): ν˜ 
= 1647, 1704, 1728, 3462 cm–1. 1H NMR (400 MHz, CDCl3, 25°C): δ = 1.40 (t, J = 7.1 Hz, 3 H), 
2.17–2.25 (m, 2 H), 2.96 (s, 3 H), 4.39 (q, J = 7.1 Hz, 2 H), 4.60 (t, J = 6.4 Hz, 1 H), 5.17 (s, 1 
H), 5.37 (s, 1 H), 5.83 (s, 1 H), 6.78–7.44 (m, 13 H), 9.12 (s, 1 H) ppm. 13C NMR (100 MHz, 
CDCl3, 25°C): δ = 14.2 (q), 27.1 (q), 38.3 (t), 60.4 (d), 63.0 (t), 79.0 (d), 114.1 (dd, 2JC-F = 24.3 
Hz), 118.0 (s), 118.3 (dd, 3JC-F = 7.5 Hz), 118.5 (dd, 2JC-F = 22.4 Hz), 121.5 (s), 121.8 (t), 
126.6 (d), 128.2 (d), 128.3 (d, overlapped), 128.6 (d), 129.2 (d), 136.1 (s), 136.3 (s), 137.3 (s), 
144.2 (s), 157.4 (d, 1JC-F = 243.0 Hz), 159.3 (s), 167.3 (s), 169.1 (s) ppm. MS: m/z = 562 [M]+. 
C30H28ClFN4O4 (563.02): calcd. C 64.00, H 5.01, N 9.95; found C 63.81, H 5.13, N 10.07. 
 
General Procedure for the Synthesis of Compounds 55 
A solution of 53 (0.2 mmol) in toluene (9 mL) was treated with TEA (0.11 mL, 0.8 mmol) and 
heated at reflux for 24 h. The organic layer was washed with aq. NaHCO3 (10 mL) and water 
(20 mL) and then it was dried with Na2SO4. The solvent was evaporated under reduced 
pressure and the products purified by silica gel column chromatography with light petroleum 
ether/AcOEt (1:1) as eluent. 
 
       Ethyl (3aS,3bR,6S)-4,6-Dimethyl-5,8-dioxo-3a-phenyl-3,3a,3b,4,5,6- 
             hexahydro-8H-benzo[e]imidazo[1,2-a]pyrazolo[5,1-c][1,4]diazepine- 
             2-carboxylate (55a) 
Yield 55%; yellow crystals; m.p. 90°C (iPr2O). [α]D 25 = +667.0 (c = 0.20, CHCl3). IR (Nujol): ν˜ 
= 1652, 1705, 1716 cm–1. 1H NMR (400 MHz, CDCl3, 25°C): δ = 0.32 (d, J = 6.8 Hz, 3 H), 1.37 
(t, J = 7.1 Hz, 3 H), 3.25 (s, 3 H), 3.60 (d, J =16.1 Hz, 1 H), 3.82 (d, J = 16.1 Hz, 1 H), 4.25 (q, J 
= 6.8 Hz), 4.33 (q, J = 7.1 Hz, 2 H), 5.57 (s, 1 H), 7.13 (dd, J = 7.4, 8.0 Hz, 1 H), 7.18–7.21 (m, 2 
H), 7.36–7.38 (m, 3 H), 7.52 (ddd, J = 1.6, 7.4, 8.7 Hz, 1 H), 7.84 (d, J = 8.7 Hz, 1 H), 8.11 (dd, J 
= 1.6, 8.0 Hz, 1 H) ppm. 13C NMR (100 MHz, CDCl3, 25°C): δ = 14.2 (q), 14.6 (q), 30.5 (q), 44.7 
(t), 55.9 (d), 62.4 (t), 77.4 (d), 81.7 (s), 116.8 (s), 118.1 (d), 122.4 (d), 126.5 (d), 129.5 (d), 129.9 
(d), 133.3 (d), 134.0 (d), 137.9 (s), 141.5 (s), 143.4 (s), 162.1 (s), 164.5 (s), 172.4 (s) ppm. MS: 
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m/z = 432 [M]+. C24H24N4O4 (432.47): calcd. C 66.65, H 5.59, N 12.96; found C 66.41, H 5.70, N 
12.82. 
 
       Ethyl (3aS,3bR,6S)-10-Chloro-4,6-dimethyl-5,8-dioxo-3a-phenyl-       
             3,3a,3b,4,5,6-hexahydro-8H-benzo[e]imidazo[1,2-a]pyrazolo[5,1-c]- 
             [1,4]diazepine-2-carboxylate (55aa) 
Yield 62%; yellow crystals; m.p. 143°C (iPr2O). [α]D 25 = +89.7 (c = 2.31, CHCl3). IR (Nujol): 
ν˜ = 1647, 1704, 1728 cm–1. 1H NMR (400 MHz, CDCl3, 25°C): δ = 0.32 (d, J = 6.7 Hz, 3 H), 
1.33 (t, J = 7.0 Hz, 3 H), 3.21 (s, 3 H), 3.57 (d, J = 16.1 Hz, 1 H), 3.82 (d, J = 16.1 Hz, 1 H), 4.17 
(q, J = 6.7 Hz, 1 H), 4.28 (q, J = 7.0 Hz, 2 H), 5.53 (s, 1 H), 7.11–7.40 (m, 6 H), 7.76–7.79 (m, 1 
H), 8.04 (s, 1 H) ppm. 13C NMR (100 MHz, CDCl3, 25°C): δ = 13.7 (q), 14.2 (q), 30.1 (q), 44.4 (t), 
55.5 (d), 62.1 (t), 76.7 (d), 81.1 (s), 117.2 (s), 119.3 (d), 126.6 (d), 127.2 (s), 129.1 (d), 129.6 (d), 
132.1 (d), 133.4 (d), 137.2 (s), 139.7 (s), 143.5 (s), 161.4 (s), 162.7 (s), 171.8 (s) ppm. MS: m/z = 
466 [M]+. C24H23ClN4O4 (466.92): calcd. C 61.74, H 4.97, N 12.00; found C 61.48, H 5.23, N 
12.27. 
 
      Ethyl (3aS,3bR,6S)-10-Fluoro-4,6-dimethyl-5,8-dioxo-3a-phenyl- 
             3,3a,3b,4,5,6-hexahydro-8H-benzo[e]imidazo[1,2-a]pyrazolo[5,1-c]- 
             [1,4]diazepine-2-carboxylate (55ab) 
Yield 71%; white crystals; m.p. 145°C (iPr2O). [α]D 25 = +912.1 (c = 3.23, CHCl3). IR (Nujol): ν˜ 
= 1655, 1690, 1724 cm–1. 1H NMR (400 MHz, CDCl3, 25°C): δ = 0.29 (d, J = 6.7 Hz, 3 H), 1.35 
(t, J = 7.1 Hz, 3 H), 3.24 (s, 3 H), 3.58 (d, J = 16.1 Hz, 1 H), 3.82 (d, J = 16.1 Hz, 1 H), 4.21 (q, J 
= 6.7 Hz, 1 H), 4.31 (q, J = 7.1 Hz, 2 H), 5.54 (s, 1 H), 7.15–7.40 (m, 6 H), 7.78–7.83 (m, 2 H) 
ppm. 13C NMR (100 MHz, CDCl3, 25°C): δ = 13.7 (q), 14.2 (q), 30.1 (q), 44.4 (t), 55.6 (d), 62.0 (t), 
76.7 (d), 81.1 (s), 118.1 (s), 118.3 (dd, 2JC-F = 24.6 Hz), 119.7 (dd, 3JC-F = 6.7 Hz), 121.1 (dd, 
2JC-F = 22.7 Hz), 126.7 (d), 129.2 (d), 129.6 (d), 137.4 (s), 137.5 (s), 142.9 (s), 157.8 (d, 1JC-F = 
240.7 Hz), 161.5 (s), 162.8 (s), 171.8 (s) ppm. MS: m/ z = 450 [M]+. C24H23FN4O4 (450.46): calcd. 
C 63.99, H 5.15, N 12.44; found C 64.08, H 5.02, N 12.31. 
 
     Ethyl (3aS,3bR,6S)-6-Isopropyl-4-methyl-5,8-dioxo-3a-phenyl- 
             3,3a,3b,4,5,6-hexahydro-8H-benzo[e]imidazo[1,2-a]pyrazolo[5,1-c]-   
             [1,4]diazepine-2-carboxylate (55b) 
Yield 62 %; yellow crystals; m.p. 138°C (iPr2O). [α]D 25 = +975.0 (c = 0.38, CHCl3). IR (Nujol): 
ν˜ = 1644, 1702, 1720 cm–1. 1H NMR (400 MHz, CDCl3, 25°C): δ = 0.16 (qqd, J = 6.6, 6.7, 9.8 
Hz, 1 H), 0.45 (d, J = 6.7 Hz, 3 H), 0.81 (d, J = 6.6 Hz, 3 H), 1.36 (t, J = 7.1 Hz, 3 H), 3.20 (s, 3 
H), 3.55 (d, J = 15.9 Hz, 1 H), 3.76 (d, J = 15.9 Hz, 1 H), 4.04 (d, J = 9.8 Hz, 1 H), 4.32 (q, J = 
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7.1 Hz, 2 H), 5.42 (s, 1 H), 7.12 (dd, J = 7.3, 8.1 Hz, 1 H), 7.26–7.37 (m, 5 H), 7.50 (ddd, J = 1.6, 
7.3, 8.6 Hz, 1 H), 7.80 (d, J = 8.6 Hz, 1 H), 8.19 (dd, J = 1.6, 8.1 Hz, 1 H) ppm. 13C NMR (100 
MHz, CDCl3, 25°C): δ = 14.6 (q), 19.3 (q), 22.2 (q), 30.1 (d), 33.3 (q), 45.0 (t), 62.5 (t), 63.5 (d), 
79.9 (d), 81.1 (s), 116.7 (s), 118.5 (d), 122.4 (d), 127.7 (d), 129.3 (d), 129.7 (d), 133.7 (d), 134.4 
(d), 137.8 (s), 142.3 (s), 145.6 (s), 161.9 (s), 166.5 (s), 172.1 (s) ppm. MS: m/z = 460 [M]+. 
C26H28N4O4 (460.52): calcd. C 67.81, H 6.13, N 12.17; found C 67.54, H 6.24, N 12.02. 
 
      Ethyl (3aS,3bR,6S)-10-Chloro-6-isopropyl-4-methyl-5,8-dioxo-3aphenyl- 
             3,3a,3b,4,5,6-hexahydro-8H-benzo[e]imidazo[1,2-a]pyrazolo-[5,1-   
             c][1,4]diazepine-2-carboxylate (55ba) 
Yield 53%; yellow crystals; m.p. 135°C (iPr2O). [α]D 25 = +818.0 (c = 3.94, CHCl3). IR (Nujol): 
ν˜ = 1652, 1688, 1716 cm–1. 1H NMR (400 MHz, CDCl3, 25°C): δ = 0.18 (qqd, J = 6.6, 6.5, 9.7 
Hz, 1 H), 0.42 (d, J = 6.6 Hz, 3 H), 0.80 (d, J = 6.5 Hz, 3 H), 1.36 (t, J = 7.2 Hz, 3 H), 3.20 (s, 
3 H), 3.56 (d, J = 16.1 Hz, 1 H), 3.76 (d, J = 16.1 Hz, 1 H), 4.03 (d, J = 9.7 Hz, 1 H), 4.32 (q, J = 
7.2 Hz, 2 H), 5.42 (s, 1 H), 7.22–7.44 (m, 6 H), 7.79 (d, J = 9.1 Hz, 1 H), 8.18 (s, 1 H) ppm. 13C 
NMR (100 MHz, CDCl3, 25°C): δ = 14.2 (q), 18.9 (q), 21.7 (q), 29.8 (d), 32.9 (q), 44.7 (t), 62.2 (t), 
63.2 (d), 76.5 (d), 80.6 (s), 117.1 (s), 119.7 (d), 127.1 (d), 127.4 (s), 129.0 (d), 129.4 (d), 132.6 (d), 
133.8 (d), 137.1 (s), 140.4 (s), 145.3 (s), 161.4 (s), 164.8 (s), 171.5 (s) ppm. MS: m/z = 494 [M]+. 
C26H27ClN4O4 (494.97): calcd. C 63.09, H 5.50, N 11.32; found C 63.27, H 5.29, N 11.44. 
 
Ethyl (3aS,3bR,6S)-10-Fluoro-6-isopropyl-4-methyl-5,8-dioxo-3aphenyl- 
             3,3a,3b,4,5,6-hexahydro-8H-benzo[e]imidazo[1,2-a]pyrazolo-[5,1- 
             c][1,4]diazepine-2-carboxylate (55bb) 
Yield 46%; yellow crystals; m.p. 144°C (iPr2O). [α]D 25 = +207.4 (c = 2.23, CHCl3). IR 
(Nujol): ν˜ = 1644, 1701, 1733 cm–1. 1H NMR (400 MHz, CDCl3, 25°C): δ = 0.07 (d, J = 6.6 Hz, 
3 H), 0.45 (qqd, J = 6.6, 6.5, 9.1 Hz, 1 H), 0.82 (d, J = 6.5 Hz, 3 H), 1.22 (t, J = 7.2 Hz, 3 H), 
3.19 (s, 3 H), 3.53 (d, J = 16.0 Hz, 1 H), 3.75 (d, J = 16.0 Hz, 1 H), 4.02 (d, J = 9.1 Hz, 1 H), 
4.31 (q, J = 7.2 Hz, 2 H), 5.32 (s, 1 H), 7.10–7.83 (m, 8 H) ppm. 13C NMR (100 MHz, CDCl3, 
25°C): δ = 14.2 (q), 18.9 (q), 21.9 (q), 29.7 (d), 32.8 (q), 44.5 (t), 62.1 (t), 63.1 (d), 76.5 (d), 81.2 
(s), 114.5 (d), 118.7 (d), 119.3 (dd, 2JC-F = 23.7 Hz), 120.0 (dd, 3JC-F = 7.5 Hz), 125.2 (dd, 
2JC-F = 22.4 Hz), 127.2 (d), 127.3 (d), 137.5 (s), 137.8 (s), 143.2 (s), 156.9 (d, 1JC-F = 244.1 
Hz), 160.8 (s), 163.0 (s), 170.6 (s) ppm. MS: m/ z = 478 [M]+. C26H27FN4O4 (478.52): calcd. C 
65.26, H 5.69, N 11.71; found C 65.51, H 5.44, N 11.43. 
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   Ethyl (3aS,3bR,6S)-6-Benzyl-4-methyl-5,8-dioxo-3a-phenyl-3,3a,3b,4,5,6- 
             hexahydro-8H-benzo[e]imidazo[1,2-a]pyrazolo[5,1-c]-[1,4]diazepine-2- 
             carboxylate (55c) 
Yield 65%; yellow oil. [α]D 25 = +94.6 (c = 0.20, CHCl3). IR (Nujol): ν˜ = 1643, 1691, 1735 cm–1. 
1H NMR (400 MHz, CDCl3, 25°C): δ = 0.82–0.91 (m, 1 H), 1.39 (t, J = 7.1 Hz, 3 H), 2.34–2.38 
(m, 1 H), 3.24 (s, 3 H), 3.64 (d, J = 16.1 Hz, 1 H), 3.84 (d, J = 16.1 Hz, 1 H), 4.29–4.38 (m, 3 H), 
5.56 (s, 1 H), 7.15–8.16 (m, 14 H) ppm. 13C NMR (100 MHz, CDCl3, 25°C): δ = 14.6 (q), 28.7 (q), 
35.0 (t), 44.7 (t), 60.6 (d), 60.8 (t), 76.8 (d), 81.7 (s), 116.8 (s), 118.2 (d), 122.5 (d), 126.8 (d), 
127.5 (d), 128.5 (d), 129.6 (d), 129.8 (d), 130.2 (d), 133.3 (d), 134.1 (d), 137.9 (s), 138.3 (s), 141.6 
(s), 143.7 (s), 162.0 (s), 164.5 (s), 171.2 (s) ppm. MS: m/z = 508 [M]+. C30H28N4O4 (508.57): calcd. 
C 70.85, H 5.55, N 11.02; found C 70.69, H 5.67, N 11.13. 
 
      Ethyl (3aS,3bR,6S)-6-Benzyl-10-chloro-4-methyl-5,8-dioxo-3aphenyl-   
             3,3a,3b,4,5,6-hexahydro-8H-benzo[e]imidazo[1,2-a]pyrazolo-[5,1-  
             c][1,4]diazepine-2-carboxylate (55ca) 
Yield 44%; yellow crystals; m.p. 141°C (iPr2O). [α]D 25 = +914.0 (c = 1.89, CHCl3). IR 
(Nujol): ν˜ = 1641, 1708, 1722 cm–1. 1H NMR (400 MHz, CDCl3, 25°C): δ = 0.86–0.92 (m, 1 H), 
1.37 (t, J = 7.2 Hz, 3 H), 2.18–2.26 (m, 1 H), 3.23 (s, 3 H), 3.64 (d, J = 16.1 Hz, 1 H), 3.83 (d, J 
= 16.1 Hz, 1 H), 4.33–4.41 (m, 3 H), 5.52 (s, 1 H), 7.13–8.13 (m, 13 H) ppm. 13C NMR (100 
MHz, CDCl3, 25°C): δ = 14.2 (q), 30.3 (q), 34.6 (t), 44.5 (t), 60.3 (d), 62.2 (t), 76.3 (d), 81.1 (s), 
117.2 (s), 119.4 (d), 126.5 (d), 126.9 (d), 127.7 (s), 128.2 (d), 129.2 (d), 129.3 (d), 129.9 (d), 132.2 
(d), 133.6 (d), 137.2 (s), 137.8 (s), 139.7 (s), 143.6 (s), 161.4 (s), 162.7 (s), 170.7 (s) ppm. MS: m/z 
= 542 [M]+. C30H27ClN4O4 (543.01): calcd. C 66.36, H 5.01, N 10.32; found C 66.12, H 5.14, N 
10.55. 
 Ethyl (3aS,3bR,6S)-6-Benzyl-10-fluoro-4-methyl-5,8-dioxo-3aphenyl- 
             3,3a,3b,4,5,6-hexahydro-8H-benzo[e]imidazo[1,2-a]pyrazolo-[5,1-  
             c][1,4]diazepine-2-carboxylate (55cb) 
Yield 77%; yellow crystals; m.p. 146°C (iPr2O). [α]D 25 = +0.64 (c = 2.2, CHCl3). IR (Nujol): ν˜ = 
1646, 1692, 1734 cm–1. 1H NMR (400 MHz, CDCl3, 25°C): δ = 0.82–0.88 (m, 1 H), 1.37 (t, J = 
7.1 Hz, 3 H), 2.30–2.35 (m, 1 H), 3.23 (s, 3 H), 3.62 (d, J = 16.0 Hz, 1 H), 3.82 (d, J = 16.0 Hz, 1 
H), 4.31–4.37 (m, 3 H), 5.53 (s, 1 H), 7.13–7.79 (m, 13H) ppm. 13C NMR (100 MHz, CDCl3, 25 
°C): δ = 14.2 (q), 29.9(q), 34.6 (t), 44.2 (t), 60.3 (d), 62.0 (t), 76.4 (d), 81.2 (s), 114.0 (s), 119.7 
(dd, 2JC-F = 23.2 Hz), 120.2 (dd, 3JC-F = 7.4 Hz), 125.6 (dd, 2JC-F = 21.8 Hz), 126.4 (d), 127.1 
(s), 128.1 (d), 129.2 (d), 129.8 (d), 130.2 (d), 130.3 (d), 135.4 (s), 137.6 (s), 137.9 (s), 142.1 (s), 
157.8 (d, 1JC-F = 245.6 Hz), 164.0 (s), 170.8 (s) ppm. MS: m/z = 526 [M]+. C30H27FN4O4 
(526.56): calcd. C 68.43, H 5.17, N 10.64; found C 68.20, H 5.34, N 10.88. 
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CHAPTER 4 
General procedure for palladium catalyzed reactions: 1 mmole of isoxazol-5-one was 
dissolved in the solvent, 4 mmole of acrylate and 0.1 mmole of Palladium acetate was added. 
The solution was refluxed for 24 hours under 1 atm of oxygen. After cooling at RT, solvent was 
removed under reduced pressure. The residue was diluted with water, extracted 3 times with 
CH2Cl2 and the combined organic layer was washed with brine; then it was dried with Na2SO4. 
The solvent was evaporated under reduced pressure and the products purified by silica gel 
column chromatography with light petroleum ether/ CH2Cl2 (1:1) as eluent. 
General procedure for gold catalyzed reactions: 1 mmole of isoxazol-5-one was dissolved 
in the solvent, 4 mmole of acrylate and 0.02 mmole of AuCl3 was added. The solution was 
refluxed for 24 hours. After cooling at RT, solvent was removed under reduced pressure. The 
residue was diluted with water, extracted 3 times with CH2Cl2 and the combined organic layer 
was washed with brine; then it was dried with Na2SO4. The solvent was evaporated under 
reduced pressure and the products purified by silica gel column chromatography with light 
petroleum ether/ CH2Cl2 (1:1) as eluent. 
 
For compound 56a and 56b see Marchesini et al.  J.Het.Chem. 1980, 763. 
Ethyl 3-(4-benzyl-3-methyl-5-oxo-4,5-dihydroisoxazol-4-yl)acrylate 57a 
Yield: with Pd catalysis DMF/THF 2/1 as solvent: 25%. With Au catalysis CH3CN as solvent: 
40%.  ; yellow oil;  1H NMR δ = 1.31 (t, J = 7.1 Hz, 3 H), 2.12 (s, 3 H), 3.08-3.38 (AB system, 
2H, J = 13.6, 44.8 Hz), 4.24 (q, J = 7.1 Hz, 2H), 6.15 (d, J = 15.7 Hz, 1H), 6.84 (d, J = 15.7 Hz, 
1H), 7.09-7.14 (m, 2H), 7.28-7.33 (m, 3H) ppm. 13C NMR δ = 13.1 (q), 14.1 (q), 40.2 (t), 58.5 (s), 
61.5 (t), 125.9 (d), 128.5 (d), 129.2 (d, 2C), 129.5 (d, 2C),132.7 (s),  138.7 (d), 165.1 (s), 166.1 (s), 
177.0 (s) ppm. MS: m/z = 288,1 [M+H]+.  
Ethyl 3-(3-methyl-5-oxo-4-phenyl-4,5-dihydroisoxazol-4-yl)acrylate 57b 
Unisolable traces;  1H NMR after elaboration shows peak compatible with this product mixed 
with by-products. MS presents a peak m/z = 274.1 [M+H]+ compatible with this product  
Ethyl 3-(4-benzyl-3-methyl-5-oxoisoxazol-2(5H)-yl)acrylate 58a 
Best yield (AcOH/Dioxane 3/1) 10%; yellow oil;  1H NMR δ = 1.31 (t, J = 7.1 Hz, 3 H), 2.12 (s, 3 
H), 3.70 (s, 2H), 4.24 (q, J = 7.1 Hz, 2H), 5.75 (d, J = 13.2 Hz, 1H), 7.08-7.16 (m, 2H), 7.27-7.37 
(m, 3H), 7.53 (d, J = 13.2 Hz, 1H), ppm. 13C NMR δ = 13.9 (q), 14.5 (q), 39.2 (t), 61.5 (t), 100.3 
(s), 102.2 (d), 125.9 (d), 129.2 (d, 2C), 129.5 (d, 2C), 139.9 (s), 140.7 (d), 145.1 (s), 166.4 (s), 
171.0 (s) ppm. MS: m/z = 288,1 [M+H]+.  
Ethyl 3-(3-methyl-5-oxo-4-phenylisoxazol-2(5H)-yl)acrylate 58b 
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Best yield (AcOH/Dioxane 3/1) 10%; yellow oil;  1H NMR δ = 1.31 (t, J = 7.1 Hz, 3 H), 2.48 (s, 3 
H), 4.24 (q, J = 7.1 Hz, 2H), 5.85 (d, J = 13.2 Hz, 1H), 7.35-7.46 (m, 5H),7.66 (d, J = 13.2 Hz, 
1H), ppm. 13C NMR δ = 14.0 (q), 14.3 (q), 61.3 (t), 99.3 (d), 105.2 (s), 126.8 (d), 128.2 (d, 2C), 
128.3 (d, 2C), 133.9 (s), 140.5 (d), 143.1 (s), 165.2 (s), 165.4 (s) ppm. MS: m/z = 274,1 [M+H]+.  
Ethyl 3-(4-benzyl-3-methylisoxazol-5-yloxy)acrylate 59a 
Best yield: unisolable traces;  1H NMR after elaboration shows peak compatible with this 
product mixed with by-products. MS presents a peak m/z = 288.1 [M+H]+ compatible with this 
product  
Ethyl 3-(3-methyl-4-phenylisoxazol-5-yloxy)acrylate 59b 
Best yield: unisolable traces;  1H NMR after elaboration shows peak compatible with this 
product mixed with by-products. MS presents a peak m/z = 274.1 [M+H]+ compatible with this 
product. 
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